Per Morten Sandset

• Wang, He-Ling; Siow, Richard; Schmauck-Medina, Tomas; Zhang, Jianying; Sandset, Per Morten & Filshie, Clare [Vis alle 38 forfattere av denne artikkelen] (2024). Meeting Summary of The NYO3 5th NO-Age/AD Meeting and the 1st Norway-UK Joint Meeting on Aging and Dementia: Recent Progress on the Mechanisms and Interventional Strategies. The journals of gerontology. Series A, Biological sciences and medical sciences. ISSN 1079-5006. 79(4). doi: 10.1093/gerona/glae029.
• Tinholt, Mari; Tekpli, Xavier; Torland, Anne Vold; Tahiri, Andliena; Geisler, Jürgen & Kristensen, Vessela [Vis alle 8 forfattere av denne artikkelen] (2024). The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. doi: 10.1016/j.jtha.2024.01.003.
• Shapiro, Amy D.; Nakar, Charles; Parker, Joseph M.; Thibaudeau, Karen; Crea, Roberto & Sandset, Per Morten (2023). Plasminogen, human-tvmh for the treatment of children and adults with plasminogen deficiency type 1. Haemophilia. ISSN 1351-8216. doi: 10.1111/hae.14849. Fulltekst i vitenarkiv
• Harrison, Sean Philip; Siller, Richard; Tanaka, Yoshiaki; Chollet Dugarte, Maria Eugenia; de la Morena-Barrio, María Eugenia & Xiang, Yangfei [Vis alle 36 forfattere av denne artikkelen] (2023). Scalable production of tissue-like vascularized liver organoids from human PSCs. Experimental and Molecular Medicine. ISSN 1226-3613. 55, s. 2005–2024. doi: 10.1038/s12276-023-01074-1. Fulltekst i vitenarkiv
• Larsen, Trine-Lise; Svalastoga, Marte; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Garresori, Herish [Vis alle 16 forfattere av denne artikkelen] (2023). Arterial events in cancer patients treated with apixaban for venous thrombosis. Thrombosis Research. ISSN 0049-3848. 228, s. 128–133. doi: 10.1016/j.thromres.2023.05.017.
• Pradier, Michelle; Rodger, Marc A.; Ghanima, Waleed; Kovacs, Michael J.; Shivakumar, Sudeep & Kahn, Susan R. [Vis alle 10 forfattere av denne artikkelen] (2023). Performance and Head-to-Head Comparison of Three Clinical Models to Predict Occurrence of Postthrombotic Syndrome: A Validation Study. Thrombosis and Haemostasis. ISSN 0340-6245. 123(7), s. 692–699. doi: 10.1055/a-2039-3388.
• Roman, Giacomo; Stavik, Benedicte; Lauritzen, Knut Husø; Sandset, Per Morten; Harrison, Sean & Sullivan, Gareth John [Vis alle 7 forfattere av denne artikkelen] (2023). “iPSC-derived liver organoids and inherited bleeding disorders: Potential and future perspectives”. Frontiers in Physiology. ISSN 1664-042X. 14. doi: 10.3389/fphys.2023.1094249. Fulltekst i vitenarkiv
• Garabet, Lamya Samir Noori; Eriksson, Anna Maria; Tjønnfjord, Eirik; Cui, Xueyan; Olsen, Magnus Kringstad & Jacobsen, Hege [Vis alle 18 forfattere av denne artikkelen] (2022). SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 7(1). doi: 10.1016/j.rpth.2022.100002. Fulltekst i vitenarkiv
• Cui, Xueyan; Stavik, Benedicte; Thiede, Bernd; Sandset, Per Morten & Kanse, Sandip (2022). FSAP Protects against Histone-Mediated Increase in Endothelial Permeability In Vitro. International Journal of Molecular Sciences. ISSN 1661-6596. 23(22). doi: 10.3390/ijms232213706. Fulltekst i vitenarkiv
• Etscheid, Michael; Hanschmann, Kay Martin; Sandset, Per Morten & Kanse, Sandip (2022). Development of a Factor VII Activating Protease (FSAP) generation assay and its application in studying FSAP in venous thrombosis. Thrombosis Research. ISSN 0049-3848. 220, s. 24–34. doi: 10.1016/j.thromres.2022.09.027. Fulltekst i vitenarkiv
• Ng, Sara; Rodger, Marc A.; Ghanima, Waleed; Kovacs, Michael J.; Shivakumar, Sudeep & Kahn, Susan R. [Vis alle 10 forfattere av denne artikkelen] (2022). External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome. Thrombosis and Haemostasis. ISSN 0340-6245. 122(8), s. 1379–1383. doi: 10.1055/a-1738-1313.
• de la Morena-Barrio, Maria Eugenia; Suchon, Pierre; Jacobsen, Eva-Marie; Iversen, Nina; Miñano, Antonia & de la Morena-Barrio, Belén [Vis alle 17 forfattere av denne artikkelen] (2022). Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood. ISSN 0006-4971. 140(2), s. 140–151. doi: 10.1182/blood.2021014708. Vis sammendrag

  Antithrombin deficiency, the most severe congenital thrombophilia, might be underestimated, as some pathogenic variants are not detected by routine functional methods. We have identified 2 new SERPINC1 variants, p.Glu227Lys and p.Asn224His, in 4 unrelated thrombophilic patients with early and recurrent thrombosis that had normal antithrombin activity. In one case, the mutation was identified by whole genome sequencing, while in the 3 remaining cases, the mutation was identified by sequencing SERPINC1 based on a single functional positive finding supporting deficiency. The 2 variants shared a common functional defect, an impaired or null N-glycosylation of Asn224 according to a eukaryotic expression model. Carriers had normal anti-FXa or anti-FIIa activities but impaired anti-FVIIa activity and a detectable loss of inhibitory function when incubating the plasma for 1 hour at 41°C. Moreover, the b glycoform of the variants, lacking 2 N-glycans, had reduced secretion, increased heparin affinity, no inhibitory activity, and a potential dominant–negative effect. These results explain the increased thrombin generation observed in carriers. Mutation experiments reflected the role that Lysine residues close to the N-glycosylation sequon have in impairing the efficacy of N-glycosylation. Our study shows new elements involved in the regulation of N-glycosylation, a key posttranslational modification that, according to our results, affects folding, secretion, and function, providing new evidence of the pathogenic consequence of an incorrect N-glycosylation of antithrombin. This study supports that antithrombin deficiency is underestimated and encourages the development of new functional and genetic tests to diagnose this severe thrombophilia.

• Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie [Vis alle 15 forfattere av denne artikkelen] (2022). Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 20(5), s. 1166–1181. doi: 10.1111/jth.15666. Fulltekst i vitenarkiv Vis sammendrag

  Background There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban for 30 months, after initial 6 months of full-dose treatment. Methods We included 298 patients with cancer and any type of VTE in a single arm interventional clinical trial. All patients were treated with full-dose apixaban (5 mg twice daily) for 6 months. Total 196 patients with active cancer after 6 months treatment continued with apixaban 2.5 mg twice daily for another 30 months. The main endpoints were recurrent VTE, major bleeding and clinically relevant non-major bleeding. Results During the 30 months of treatment with low-dose apixaban 14 (7.6%; 95% confidence interval (CI) 4.0%–11.7%) patients experienced recurrent VTE, six (3.1%; 95% CI 1.1%–6.5%) experienced major bleeding and 16 (8.1%, 95% CI: 4.7%–12.8%) experienced clinically relevant non-major bleeding. The incidence rate per person month of recurrent VTE was 0.8% (95% CI 0.41–1.6) at 2–6 months with full-dose apixaban, and 1.0% (95% CI 0.5–1.9) at 7–12 months with low-dose apixaban. The incidence rate of major bleeding was 1.1% (95% CI 0.6–2.0) at 2–6 months, and 0.3% (95% CI 0.1–1.0) at 7–12 months. Between 12 and 36 months the incidence rate of recurrent VTE and major bleedings remained low. Conclusion Dose reduction of apixaban to 2.5 mg twice daily seems safe after 6 months of full-dose treatment. After 12 months the incidence rate of recurrent VTE and major bleeding remained low.

• Delluc, Aurélien; Ghanima, Waleed; Kovacs, Michael J.; Shivakumar, Sudeep; Kahn, Susan R. & Sandset, Per Morten [Vis alle 9 forfattere av denne artikkelen] (2022). Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER). Thrombosis Research. ISSN 0049-3848. 213, s. 119–124. doi: 10.1016/j.thromres.2022.03.014.
• Skaga, Nils Oddvar; Holtan, Anders; Inger, Haug & Sandset, Per Morten (2022). KOAGULASJONSBOKS PÅ TRAUMESTUA I AKUTTMOTTAKET OSLO UNIVERSITETSSYKEHUS – ULLEVÅL (Versjon VI, 16.02.2022). Kirurgen. ISSN 1504-8888. s. 21–25.
• Skaga, Nils Oddvar; Holtan, Anders; Haug, Inger & Sandset, Per Morten (2022). MEDIKAMENTBRUK VED KRITISK BLØDNING OG REVERSERING AV ANTITROMBOTISKE LEGEMIDLER – PROTOKOLL I TRAUMEMOTTAKET VED OUS ULLEVÅL. Kirurgen. ISSN 1504-8888. s. 20–21.
• Martin, Karlyn A.; Beyer-Westendorf, Jan; Davidson, Bruce L.; Huisman, Menno V.; Sandset, Per Morten & Moll, S. (2021). Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 19(8), s. 1874–1882. doi: 10.1111/jth.15358.
• Andersen, Elisabeth; Dugarte, Maria Eugenia Chollet; Bernardi, Francesco; Branchini, Alessio; Baroni, Marcello & Mariani, Guglielmo [Vis alle 12 forfattere av denne artikkelen] (2021). The factor vii variant p.A354v-p.p464hfs: Clinical versus intracellular and biochemical phenotypes induced by chemical chaperones. Applied Sciences. ISSN 2076-3417. 11(13). doi: 10.3390/app11135762. Fulltekst i vitenarkiv
• Andresen, Marianne Seierstad; Sletten, Marit; Sandset, Per Morten; Iversen, Nina; Stavik, Benedicte & Tinholt, Mari (2021). Coagulation Factor v (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells. Thrombosis and Haemostasis. ISSN 0340-6245. 122(8), s. 1288–1295. doi: 10.1055/a-1707-2130.
• Delluc, Aurélien; Ghanima, Waleed; Kovacs, Michael J.; Shivakumar, Sudeep; Kahn, Susan R. & Sandset, Per Morten [Vis alle 9 forfattere av denne artikkelen] (2021). Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 20(1), s. 126–132. doi: 10.1111/jth.15537.
• Ihle-Hansen, Håkon; Hagberg, Guri; Sandset, Else Charlotte; Ihle-Hansen, Hege; Amundsen, Erik Koldberg & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2021). Reversering av antikoagulerende legemidler ved hjerneblødning. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 141(14), s. 1–6. doi: 10.4045/tidsskr.21.0063. Fulltekst i vitenarkiv
• Wik, Hilde Skuterud; Kahn, Susan; Eriksson, Henry; Morrison, David; Ghanima, Waleed & Schulman, Sam [Vis alle 7 forfattere av denne artikkelen] (2021). Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. s. 1–9. doi: 10.1111/jth.15449. Fulltekst i vitenarkiv
• Jacobsen, Anne Flem & Sandset, Per Morten (2021). Prior Thromboembolic Disease and Assisted Reproductive Therapy. Seminars in Reproductive Medicine. ISSN 1526-8004. doi: 10.1055/s-0041-1732375. Fulltekst i vitenarkiv
• Cui, Xueyan; Tjønnfjord, Geir Erland; Kanse, Sandip; Dahm, Anders Erik A; Iversen, Nina & Myklebust, Christiane Filion [Vis alle 12 forfattere av denne artikkelen] (2021). Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Scientific Reports. ISSN 2045-2322. 11. doi: 10.1038/s41598-021-84695-8. Fulltekst i vitenarkiv
• Khialani, Deeksha; Vasan, Sowmya; Cushman, Mary; Dahm, Anders Erik A; Sandset, Per Morten & Rossouw, Jacques [Vis alle 7 forfattere av denne artikkelen] (2021). Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 19(7), s. 1729–1737. doi: 10.1111/jth.15319.
• Engeseth, Marit; Enden, Tone Rønnaug; Sandset, Per Morten & Wik, Hilde Skuterud (2021). Predictors of long-term post-thrombotic syndrome following high proximal deep vein thrombosis: a cross-sectional study. Thrombosis Journal. ISSN 1477-9560. 19:3, s. 1–7. doi: 10.1186/s12959-020-00253-8. Fulltekst i vitenarkiv
• Bøhn, Siv Kjølsrud; Thune, Inger; Flote, Vidar Gordon; Frydenberg, Hanne; Bertheussen, Gro Falkener & Husøy, Anders [Vis alle 12 forfattere av denne artikkelen] (2021). Effects of a One-Year Physical Activity Intervention on Markers of Hemostasis among Breast Cancer Survivors - A Randomized Controlled Trial. TH Open. ISSN 2512-9465. 5(1), s. e14–e23. doi: 10.1055/s-0040-1721782. Fulltekst i vitenarkiv Vis sammendrag

  Introduction Physical activity may reduce the development of breast cancer. Whereas hypercoagulability has been linked to adverse outcomes in breast cancer patients, the effects of physical activity on their hemostatic factors are unknown. The study aimed to assess whether long-term (1 year) physical activity can affect hemostatic factors in breast cancer patients. Methods Fifty-five women (35–75 years) with invasive breast cancer stage I/II were randomized to a physical activity intervention (n = 29) lasting 1 year or to a control group (n = 26), and analyzed as intention to treat. Fibrinogen, factor VII antigen, tissue factor pathway inhibitor, and von Willebrand factor (VWF) antigen as well as prothrombin fragment 1 + 2, the endogenous thrombin potential and D-dimer, were measured in plasma before intervention (baseline), and then after 6 and 12 months. Results Maximal oxygen uptake (measure of cardiorespiratory fitness) decreased the first 6 months among the controls, but remained stable in the intervention group. We found no significant differences between the two study groups regarding any of the hemostatic factors, except a significantly higher increase in factor VII antigen in the intervention group. The effect of the intervention on VWF was, however, significantly affected by menopausal stage, and a significant effect of the intervention was found on VWF among postmenopausal women, even after adjustment for dietary intake. Conclusion Long-term physical activity had no effect on the majority of the hemostatic factors measured, but led to increased plasma concentrations of factor VII antigen and prevented an increase in VWF concentration after breast cancer treatment in postmenopausal women. The clinical impact of these findings for risk of vascular thrombosis warrants further studies.

• Tritschler, Tobias; Sandset, Per Morten; Mathieu, Marie-Eve; Skeith, Leslie; Rodger, Marc & Middeldorp, Saskia [Vis alle 34 forfattere av denne artikkelen] (2020). Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. doi: 10.1111/jth.15094.
• Harrison, Sean; Siller, Richard; Tanaka, Yoshiaki; Xiang, Yangfei; Patterson, Benjamin & Kempf, Henning [Vis alle 29 forfattere av denne artikkelen] (2020). Scalable production of tissue-like vascularised liver organoids from human PSCs. bioRxiv. ISSN 2692-8205. doi: 10.1101/2020.12.02.406835.
• Andresen, Marianne Seierstad; Stavik, Benedicte; Sletten, Marit; Tinholt, Mari; Sandset, Per Morten & Iversen, Nina [Vis alle 7 forfattere av denne artikkelen] (2020). Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells . Scientific Reports. ISSN 2045-2322. 10:4036, s. 1–10. doi: 10.1038/s41598-020-61018-x. Fulltekst i vitenarkiv
• Godolphin, Peter J.; Bath, Philip M.; Partlett, Christopher; Berge, Eivind; Brown, Martin M & Eliasziw, Misha [Vis alle 9 forfattere av denne artikkelen] (2020). Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification. European Stroke Journal. ISSN 2396-9873. 5(2), s. 174–183. doi: 10.1177/2396987320910047. Fulltekst i vitenarkiv
• Andersen, Nina Gjerde; Mowinckel, Marie-Christine; Sunde, Kjetil; Sandset, Per Morten & Beitland, Sigrid (2020). Utility of coagulation analyses to assess thromboprophylaxis with dalteparin in intensive care unit patients. Acta Anaesthesiologica Scandinavica. ISSN 0001-5172. s. 1–10. doi: 10.1111/aas.13748. Fulltekst i vitenarkiv
• Hannevik, Trine-Lise; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Ahmed, Herish & Jacobsen, Eva-Marie [Vis alle 15 forfattere av denne artikkelen] (2020). Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. Thrombosis Research. ISSN 0049-3848. 196, s. 238–244. doi: 10.1016/j.thromres.2020.08.042.
• Thorsen, Lene; Haugnes, Hege Sagstuen; Fosså, Sophie Dorothea; Brydøy, Marianne; Tandstad, Torgrim & Wisløff, Torbjørn [Vis alle 13 forfattere av denne artikkelen] (2020). Thromboembolic events after high-intensity training duringcisplatin-based chemotherapy for testicular cancer: Casereports and review of the literature. International Journal of Cancer. ISSN 0020-7136. 147(11), s. 3189–3198. doi: 10.1002/ijc.33151. Fulltekst i vitenarkiv Vis sammendrag

  The randomized “Testicular cancer and Aerobic and Strength Training trial” (TAST‐trial) aimed to evaluate the effect of high‐intensity interval training (HIIT) on cardiorespiratory fitness during cisplatin‐based chemotherapy (CBCT) for testicular cancer (TC). Here, we report on an unexpected high number of thromboembolic (TE) events among patients randomized to the intervention arm, and on a review of the literature on TE events in TC patients undergoing CBCT. Patients aged 18 to 60 years with a diagnosis of metastatic germ cell TC, planned for 3 to 4 CBCT cycles, were randomized to a 9 to 12 weeks exercise intervention, or to a single lifestyle counseling session. The exercise intervention included two weekly HIIT sessions, each with 2 to 4 intervals of 2 to 4 minutes at 85% to 95% of peak heart rate. The study was prematurely discontinued after inclusion of 19 of the planned 94 patients, with nine patients randomized to the intervention arm and 10 to the control arm. Three patients in the intervention arm developed TE complications; two with pulmonary embolism and one with myocardial infarction. All three patients had clinical stage IIA TC. No TE complications were observed among patients in the control arm. Our observations indicate that high‐intensity aerobic training during CBCT might increase the risk of TE events in TC patients, leading to premature closure of the TAST‐trial.

• Tinholt, Mari; Stavik, Benedicte; Tekpli, Xavier; Garred, Øystein; Borgen, Elin & Kristensen, Vessela N. [Vis alle 9 forfattere av denne artikkelen] (2020). Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. Oncoimmunology. ISSN 2162-4011. 9:e1824644(1), s. 1–12. doi: 10.1080/2162402X.2020.1824644. Fulltekst i vitenarkiv
• Garabet, Lamya Samir Noori; Henriksson, Carola; Lozano, Maria Luisa; Ghanima, Waleed Khalid; Bussel, James & Brodin, Ellen Elisabeth [Vis alle 11 forfattere av denne artikkelen] (2019). Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin reseptor agonists. Thrombosis Research. ISSN 0049-3848. 185, s. 119–124. doi: 10.1016/j.thromres.2019.11.031. Fulltekst i vitenarkiv
• Gregersen, Ida; Høibraaten, Else; Holven, Kirsten Bjørklund; Løvdahl, Lene; Ueland, Thor & Mowinckel, Marie-Christine [Vis alle 10 forfattere av denne artikkelen] (2019). Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women. Thrombosis Research. ISSN 0049-3848. 184, s. 1–7. doi: 10.1016/j.thromres.2019.10.005. Fulltekst i vitenarkiv
• Engeseth, Marit; Enden, Tone Rønnaug; Sandset, Per Morten & Wik, Hilde Skuterud (2019). Limitations of the Villalta scale in diagnosing post-thrombotic syndrome. Thrombosis Research. ISSN 0049-3848. 184, s. 62–66. doi: 10.1016/j.thromres.2019.10.018. Fulltekst i vitenarkiv
• Andersen, Elisabeth; Dugarte, Maria Eugenia Chollet; Baroni, Marcello; Pinotti, Mirko; Bernardi, Francesco & Skarpen, Ellen [Vis alle 8 forfattere av denne artikkelen] (2019). The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII. Cell & Bioscience. ISSN 2045-3701. 9:69, s. 1–10. doi: 10.1186/s13578-019-0333-8. Fulltekst i vitenarkiv
• Dahm, Anders Erik A; Jacobsen, Eva-Marie; Wik, Hilde Skuterud; Jacobsen, Anne Flem; Mollnes, Tom Eirik & Kanse, Sandip [Vis alle 7 forfattere av denne artikkelen] (2019). Elevated complement C3 and C4 levels are associated with postnatal pregnancy-related venous thrombosis. Thrombosis and Haemostasis. ISSN 0340-6245. 119(9), s. 1481–1488. doi: 10.1055/s-0039-1692426. Fulltekst i vitenarkiv
• Engeseth, Marit; Enden, Tone Rønnaug; Andersen, Marit Helen; Sandset, Per Morten & Wik, Hilde Skuterud (2019). Does the Villalta scale capture the essence of postthrombotic syndrome? A qualitative study of patient experience and expert opinion. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. s. 1–8. doi: 10.1111/jth.14557. Fulltekst i vitenarkiv
• Garabet, Lamya Samir Noori; Ghanima, Waleed Khalid; Hellum, Marit Synnøve; Sandset, Per Morten; Bussel, James B. & Tran, Hoa Thi Tuyet [Vis alle 7 forfattere av denne artikkelen] (2019). Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. Platelets. ISSN 0953-7104. doi: 10.1080/09537104.2019.1639655.
• Garabet, Lamya Samir Noori; Ghanima, Waleed Khalid; Rangberg, Anbjørg; Teruel-Montoya, Raul; Martinez, Constantino & Lozano, Maria Luisa [Vis alle 10 forfattere av denne artikkelen] (2019). Circulating microRNAs in patients with immune thrombocytopenia before and after treatment wirh thrombopoietin-receptor agonists. Platelets. ISSN 0953-7104. s. 1–8. doi: 10.1080/09537104.2019.1585527. Fulltekst i vitenarkiv
• Godolphin, Peter J.; Bath, Philip M.; Algra, Ale; Berge, Eivind; Brown, Christopher Martin & Chalmers, John [Vis alle 19 forfattere av denne artikkelen] (2019). Outcome assessment by central adjudicators versus site investigators in stroke trials: A systematic review and meta-analysis. Stroke. ISSN 0039-2499. 50(8), s. 2187–2196. doi: 10.1161/STROKEAHA.119.025019. Fulltekst i vitenarkiv Vis sammendrag

  Background and Purpose— In randomized stroke trials, central adjudication of a trial’s primary outcome is regularly implemented. However, recent evidence questions the importance of central adjudication in randomized trials. The aim of this review was to compare outcomes assessed by central adjudicators with outcomes assessed by site investigators. Methods— We included randomized stroke trials where the primary outcome had undergone an assessment by site investigators and central adjudicators. We searched MEDLINE, EMBASE, CENTRAL (Cochrane Central Register of Controlled Trials), Web of Science, PsycINFO, and Google Scholar for eligible studies. We extracted information about the adjudication process as well as the treatment effect for the primary outcome, assessed both by central adjudicators and by site investigators. We calculated the ratio of these treatment effects so that a ratio of these treatment effects >1 indicated that central adjudication resulted in a more beneficial treatment effect than assessment by the site investigator. A random-effects meta-analysis model was fitted to estimate a pooled effect. Results— Fifteen trials, comprising 69 560 participants, were included. The primary outcomes included were stroke (8/15, 53%), a composite event including stroke (6/15, 40%) and functional outcome after stroke measured on the modified Rankin Scale (1/15, 7%). The majority of site investigators were blind to treatment allocation (9/15, 60%). On average, there was no difference in treatment effect estimates based on data from central adjudicators and site investigators (pooled ratio of these treatment effects=1.02; 95% CI, [0.95–1.09]). Conclusions— We found no evidence that central adjudication of the primary outcome in stroke trials had any impact on trial conclusions. This suggests that potential advantages of central adjudication may not outweigh cost and time disadvantages in stroke studies if the primary purpose of adjudication is to ensure validity of trial findings.

• Skretting, Grethe; Andersen, Elisabeth; Myklebust, Christiane Filion; Sandset, Per Morten; Tinholt, Mari & Iversen, Nina [Vis alle 7 forfattere av denne artikkelen] (2019). Transcription factor FOXP3: A repressor of the TFPI gene? Journal of Cellular Biochemistry. ISSN 0730-2312. s. 1–13. doi: 10.1002/jcb.28563.
• Eilertsen, Anette Løken; Dahm, Anders Erik A; Høibraaten, Else; Lofthus, Cathrine Marie; Mowinckel, Marie-Christine & Sandset, Per Morten (2019). Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment. Blood Coagulation and Fibrinolysis. ISSN 0957-5235. 30(1), s. 17–23. doi: 10.1097/MBC.0000000000000784.
• Beitland, Sigrid; Wimmer, Rolf Henning; Lorentsen, Torleif; Jacobsen, Dag; Drægni, Tomas & Brunborg, Cathrine [Vis alle 9 forfattere av denne artikkelen] (2019). Venous thromboembolism in the critically ill: A prospective observational study of occurrence, risk factors and outcome. Acta Anaesthesiologica Scandinavica. ISSN 0001-5172. 63(5), s. 630–638. doi: 10.1111/aas.13316. Fulltekst i vitenarkiv
• Garabet, Lamya Samir Noori; Ghanima, Waleed Khalid; Jonassen, Christine Monceyron; Skov, Vibe; Holst, René & Mowinckel, Marie-Christine [Vis alle 12 forfattere av denne artikkelen] (2019). Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets. ISSN 0953-7104. 30(2), s. 206–212. doi: 10.1080/09537104.2017.1394451.
• Schultz, Nina Haagenrud; Holme, Pål Andre; Bjørnsen, Stine; Henriksson, Carola; Sandset, Per Morten & Jacobsen, Eva-Marie (2018). The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. Platelets. ISSN 0953-7104. doi: 10.1080/09537104.2018.1557618.
• Tavoly, Mazdak; Wik, Hilde Skuterud; Sirnes, Per-Anton; Jelsness-Jørgensen, Lars-Petter; Ghanima, Josef P. & Klok, Frederikus A. [Vis alle 8 forfattere av denne artikkelen] (2018). The impact of post-pulmonary embolism syndrome and its possible determinants. Thrombosis Research. ISSN 0049-3848. 171, s. 84–91. doi: 10.1016/j.thromres.2018.09.048.
• Sacco, Simona; Merki-Feld, Gabriele S.; Ægidius, Karen Lehrmann; Bitzer, Johannes; Canonico, Marianne & Gantenbein, Andreas R. [Vis alle 19 forfattere av denne artikkelen] (2018). Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: A consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). The Journal of Headache and Pain. ISSN 1129-2369. 19(76). doi: 10.1186/s10194-018-0896-5. Fulltekst i vitenarkiv
• Olsson, Maja; Stanne, Tara M.; Pedersén, Annie; Lorentzen, Erik; Kara, Emrah & Martinez-Palaciàn, Adoraciòn [Vis alle 14 forfattere av denne artikkelen] (2018). Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 16(10), s. 2024–2034. doi: 10.1111/jth.14258. Fulltekst i vitenarkiv
• Gravensteen, Ida Kathrine; Jacobsen, Eva-Marie; Sandset, Per Morten; Helgadóttir, Linda Björk; Rådestad, Ingela & Sandvik, Leiv [Vis alle 7 forfattere av denne artikkelen] (2018). Anxiety, depression and relationship satisfaction in the pregnancy following stillbirth and after the birth of a live-born baby: A prospective study. BMC Pregnancy and Childbirth. ISSN 1471-2393. 18(41). doi: 10.1186/s12884-018-1666-8. Fulltekst i vitenarkiv
• Andersen, Elisabeth; Dugarte, Maria Eugenia Chollet; Myklebust, Christiane Filion; Pinotti, Mirko; Bernardi, Francesco & Chuansumrit, Ampaiwan [Vis alle 9 forfattere av denne artikkelen] (2018). Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency. Thrombosis and Haemostasis. ISSN 0340-6245. 118(4), s. 664–675. doi: 10.1055/s-0038-1637690.
• Kostovski, Emil; Frigato, E; Savikj, Mladen; Dahm, Anders Erik A; Sandset, Per Morten & Mowinckel, Marie-Christine [Vis alle 10 forfattere av denne artikkelen] (2018). Normalization of disrupted clock gene expression in males with tetraplegia: a crossover randomized placebo-controlled trial of melatonin supplementation. Spinal Cord. ISSN 1362-4393. s. 1–8. doi: 10.1038/s41393-018-0176-x. Fulltekst i vitenarkiv
• Wik, Hilde Skuterud; Enden, Tone Rønnaug; Ghanima, Waleed Khalid; Engeseth, Marit; Kahn, Susan R. & Sandset, Per Morten (2018). Diagnostic scales for the post-thrombotic syndrome. Thrombosis Research. ISSN 0049-3848. 164, s. 110–115. doi: 10.1016/j.thromres.2017.10.022.
• Rodger, Marc; Langlois, Nicole; Middeldorp, Saskia; Kahn, Susan; Sandset, Per Morten & Brighton, Timothy [Vis alle 17 forfattere av denne artikkelen] (2018). Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. Thrombosis Research. ISSN 0049-3848. 163, s. 128–131. doi: 10.1016/j.thromres.2018.01.050.
• Shapiro, Amy D.; Nakar, Charles; Parker, Joseph M.; Albert, Gary R.; Moran, John E. & Thibaudeau, Karen [Vis alle 10 forfattere av denne artikkelen] (2018). Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. ISSN 0006-4971. 131(12), s. 1301–1310. doi: 10.1182/blood-2017-09-806729.
• Tikkinen, Kari A.O.; Craigie, Samantha; Agarwal, Arnav; Violette, Philippe D.; Novara, Giacomo & Cartwright, Rufus [Vis alle 16 forfattere av denne artikkelen] (2018). Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: systematic review and meta-analysis. European Urology. ISSN 0302-2838. 73(2), s. 242–251. doi: 10.1016/j.eururo.2017.03.008. Fulltekst i vitenarkiv
• Utne, Kristin Kornelia; Dahm, Anders Erik A; Wik, Hilde Skuterud; Jelsness-Jørgensen, Lars-Petter; Sandset, Per Morten & Ghanima, Waleed Khalid (2018). Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thrombosis Research. ISSN 0049-3848. 163, s. 6–11. doi: 10.1016/j.thromres.2018.01.013.
• Gravensteen, Ida Kathrine; Jacobsen, Eva-Marie; Sandset, Per Morten; Helgadóttir, Linda Björk; Rådestad, Ingela & Sandvik, Leiv [Vis alle 7 forfattere av denne artikkelen] (2018). Healthcare utilisation, induced labour and caesarean section in the pregnancy after stillbirth: a prospective study. BJOG: An International Journal of Obstetrics and Gynaecology. ISSN 1470-0328. 125(2), s. 202–210. doi: 10.1111/1471-0528.14750. Fulltekst i vitenarkiv
• Amundsen, Erik Koldberg; Skadberg, Øyvind; Ghanima, Waleed Khalid; Frønæs, Synne Grønvold; Dahm, Anders Erik A & Tøsdal, Margunn Bye [Vis alle 9 forfattere av denne artikkelen] (2018). D-Dimer: Aldersjusterte beslutningsgrenser ved diagnostikk av venøs tromboembolisme? Klinisk Biokemi i Norden. ISSN 1101-2013. 30(1), s. 26–36.
• Dugarte, Maria Eugenia Chollet; Andersen, Elisabeth; Skarpen, Ellen; Myklebust, Christiane Filion; Koehler, Christian & Morth, Jens Preben [Vis alle 12 forfattere av denne artikkelen] (2018). Factor VII deficiency: Unveiling the cellular and molecular mechanisms underlying Three model alterations of the enzyme catalytic domain. Biochimica et Biophysica Acta - Molecular Basis of Disease. ISSN 0925-4439. 1864(3), s. 660–667. doi: 10.1016/j.bbadis.2017.12.016.
• Schultz, Nina Haagenrud; Tran, Hoa Thi Tuyet; Bjørnsen, Stine; Henriksson, Carola Elisabeth; Sandset, Per Morten & Holme, Pål Andre (2017). The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 1(1), s. 49–56. doi: 10.1002/rth2.12015.
• Tikkinen, Kari A. O.; Craigie, Samantha; Agarwal, Arnav; Siemieniuk, Reed A.C.; Cartwright, Rufus & Violette, Philippe D. [Vis alle 16 forfattere av denne artikkelen] (2017). Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis. European Urology. ISSN 0302-2838. 73(2), s. 236–241. doi: 10.1016/j.eururo.2017.02.025.
• Sagedal, Solbjørg; Sandvik, Leiv; Klingenberg, Olav & Sandset, Per Morten (2017). β-Thromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane. Scandinavian Journal of Clinical and Laboratory Investigation. ISSN 0036-5513. 77(8), s. 679–684. doi: 10.1080/00365513.2017.1397288.
• Sacco, Simona; Merki-Feld, Gabriele S.; Ægidius, Karen Lehrmann; Bitzer, Johannes; Canonico, Marianne & Kurth, Tobias [Vis alle 15 forfattere av denne artikkelen] (2017). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). The Journal of Headache and Pain. ISSN 1129-2369. 18:108, s. 1–20. doi: 10.1186/s10194-017-0815-1.
• Cui, Xue-Yan; Skretting, Grethe; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A & Sahlberg, Kristine Kleivi [Vis alle 9 forfattere av denne artikkelen] (2017). A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. Thrombosis Research. ISSN 0049-3848. 157, s. 111–116. doi: 10.1016/j.thromres.2017.07.013.
• Krishnan, Kailash; Jusufovic, Mirza; Sandset, Per Morten & Sandset, Else Charlotte (2017). Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence. Seminars in neurology. ISSN 0271-8235. 37(3), s. 366–375. doi: 10.1055/s-0037-1603469.
• Skuterud Wik, Hilde; Ghanima, Waleed Khalid; Sandset, Per Morten & Kahn, Susan R (2017). Scoring Systems for Postthrombotic Syndrome. Seminars in Thrombosis and Hemostasis. ISSN 0094-6176. 43(5), s. 500–504. doi: 10.1055/s-0037-1599142.
• Espada Serrano, Sandra; Stavik, Benedicte; Holm, Sverre; Sagen, Ellen Lund; Bjerkeli, Vigdis & Skjelland, Mona [Vis alle 12 forfattere av denne artikkelen] (2017). Tissue factor pathway inhibitor attenuates ER stress-induced inflammation in human M2-polarized macrophages. Biochemical and Biophysical Research Communications - BBRC. ISSN 0006-291X. 491(2), s. 442–448. doi: 10.1016/j.bbrc.2017.07.070. Vis sammendrag

  Endoplasmic reticulum (ER) stress has been shown to play a key role during the initiation and clinical progression of the cardiovascular diseases, such as atherosclerosis. We have recently shown that expression of tissue factor pathway inhibitor (TFPI) in human monocyte-derived macrophages (MDMs) was induced by cholesterol crystals (CC). In the present study we aimed to determine the role of TFPI under ER stress conditions using human MDMs. qRT-PCR and immunohistochemistry analysis were performed to determine the presence of the ER stress marker CCAAT/enhancer binding protein homologous protein (CHOP) and TFPI in human carotid plaque material and also in human MDMs polarized into pro-inflammatory M1 or anti-inflammatory M2 populations. CHOP mRNA levels were upregulated in the plaques compared to healthy vessels, and CHOP protein was localized in the same area as TFPI in the plaques. Both CHOP and TFPI mRNA levels were upregulated after CC treatment, especially in the M2 phenotype, and the ER stress inhibitor 4-phenylbutyric acid (PBA) reversed this effect. Furthermore, CC treatment increased the levels of the pro-inflammatory cytokines TNF-α, IL-6, and IL-8, which for TNF-α and IL-8 was inhibited by PBA, and reduced the levels of the anti-inflammatory cytokine IL-10 in M2-polarized macrophages. Knockdown of TFPI prior to CC treatment exacerbated TNF-α and IL-6 levels, but reduced IL-8 and IL-10 levels. Our results show that CC induce TFPI and cytokine expression in M2-polarized macrophages through activation of the ER stress pathway and that TFPI has a protective effect against TNF-α and IL-6 mediated inflammation. These mechanisms may have implications for the pathogenesis of atherosclerosis.

• Stavik, Benedicte; Holm, Sverre; Espada Serrano, Sandra; Iversen, Nina; Sporsheim, Bjørnar & Bjerkeli, Vigdis [Vis alle 12 forfattere av denne artikkelen] (2017). Increased expression of TFPI in human carotid stenosis. Thrombosis Research. ISSN 0049-3848. 155, s. 31–37. doi: 10.1016/j.thromres.2017.04.024. Vis sammendrag

  INTRODUCTION: Tissue factor (TF) pathway inhibitor (TFPI) is the physiological inhibitor of TF induced blood coagulation and two isoforms exists, TFPIα and TFPIβ. In atherosclerotic plaques, TFPI may inhibit TF activity and thrombus formation, which is the main cause of ischemic stroke in carotid artery disease. We aimed to identify the isoforms of TFPI present in human carotid plaques and potential sources of TFPI. MATERIALS AND METHODS: Human atherosclerotic plaques from carotid endarterectomies were used for mRNA and immunohistochemistry analyses. hPBMCs isolated from buffy coats and THP-1 cells were differentiated and polarized into M1 or M2 macrophages, and subsequently cultured with or without cholesterol crystals (CC). mRNA and protein expression were measured with qRT-PCR and ELISA, respectively, and procoagulant activity was assessed using a two-stage chromogenic assay. RESULTS: TFPIα and TFPIβ mRNA levels were significantly increased in carotid plaques, whereas TF levels were unchanged as compared to healthy arteries. Antibodies against total TFPI showed elevated levels compared to antibodies against free TFPIα, both by immunohistochemical and ELISA detection in plaques. The antibody against total TFPI also co-localized with CD68 and the M1 and M2 markers CD80 and CD163, respectively. The TFPI mRNA expression was elevated and the procoagulant activity was decreased in M2 compared to M1 polarized human macrophages. TFPI was present in early foam cell formation and CC treatment increased the TFPI mRNA expression even further in M2 macrophages. CONCLUSIONS: Our data indicate that both isoforms of TFPI are present in advanced plaques and that anti-inflammatory M2 macrophages may be a potential source of TFPI.

• Prebensen, Christian; Trøseid, Marius; Ueland, Thor; Dahm, Anders Erik A; Sandset, Per Morten & Aaberge, Ingeborg Sundsvalen [Vis alle 10 forfattere av denne artikkelen] (2017). Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. PLOS ONE. ISSN 1932-6203. 12(5). doi: 10.1371/journal.pone.0176527. Fulltekst i vitenarkiv
• Schultz, Nina Haagenrud; Tran, Hoa Thi Tuyet; Bjørnsen, Stine; Henriksson, Carola; Sandset, Per Morten & Holme, Pål Andre (2017). The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thrombosis Journal. ISSN 1477-9560. 15(1). doi: 10.1186/s12959-017-0129-1.
• Andresen, Marianne Seierstad; Ali, Huda Omar; Myklebust, Christiane Filion; Sandset, Per Morten; Stavik, Benedicte & Iversen, Nina [Vis alle 7 forfattere av denne artikkelen] (2017). Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1. Molecular and Cellular Endocrinology. ISSN 0303-7207. 443, s. 80–88. doi: 10.1016/j.mce.2017.01.016.
• Tinholt, Mari; Sandset, Per Morten; Mowinckel, Marie-Christine; Garred, Øystein; Sahlberg, Kristine Kleivi & Kristensen, Vessela N. [Vis alle 10 forfattere av denne artikkelen] (2016). Determinants of acquired activated protein C resistance and D-dimer in breast cancer. Thrombosis Research. ISSN 0049-3848. 145, s. 78–83. doi: 10.1016/j.thromres.2016.08.003.
• Tavoly, Mazdak; Utne, Kristin Kornelia; Jelsness-Jørgensen, Lars-Petter; Skuterud Wik, Hilde; Klok, Frederikus A & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2016). Health-related quality of life after pulmonary embolism: a cross-sectional study. BMJ Open. ISSN 2044-6055. 6(11). doi: 10.1136/bmjopen-2016-013086.
• Ali, Huda Omar; Arroyo, Ana Belen V.; Gónzález-Conejero, Rocío; Stavik, Benedicte; Iversen, Nina & Sandset, Per Morten [Vis alle 8 forfattere av denne artikkelen] (2016). The role of microRNA-27a/b and microRNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor α. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 14(6), s. 1226–1237. doi: 10.1111/jth.13321.
• Bates, Shannon M.; Alonso-Coello, Pablo; Tikkinen, Kari A.O.; Ebrahim, Shanil; Lopes, Luciane Cruz & McDonald, Sarah D. [Vis alle 17 forfattere av denne artikkelen] (2016). Women's values and preferences and health state valuations for thromboprophylaxis during pregnancy: A cross-sectional interview study. Thrombosis Research. ISSN 0049-3848. 140, s. 22–29. doi: 10.1016/j.thromres.2015.12.015.
• Garabet, Lamya Samir Noori; Gilboe, Inge-Margrethe; Mowinckel, Marie-Christine; Jacobsen, Anne Flem; Mollnes, Tom Eirik & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2016). Antiphospholipid antibodies are associated with low levels of complement C3 and C4 in patients with systemic Lupus Erythematosus. Scandinavian Journal of Immunology. ISSN 0300-9475. 84(2), s. 95–99. doi: 10.1111/sji.12445.
• Utne, Kristin Kornelia; Tavoly, Mazdak; Skuterud Wik, Hilde; Jelsness-Jørgensen, Lars-Petter; Holst, René & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2016). Health-related quality of life after deep vein thrombosis. SpringerPlus. ISSN 2193-1801. 5(1). doi: 10.1186/s40064-016-2949-z.
• Martin, K.; Beyer-Westendorf, J.; Davidson, B.L.; Huisman, M.V.; Sandset, Per Morten & Moll, S. (2016). Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 14(6), s. 1308–1313. doi: 10.1111/jth.13323.
• Tiscia, Giovanni Luca; Andersen, Elisabeth; Myklebust, Christiane Filion; Grandone, E.; Sandset, Per Morten & Skretting, Grethe (2016). Functional characterization of annexin A5 gene promoter allelic variants. Thrombosis Research. ISSN 0049-3848. 144, s. 93–99. doi: 10.1016/j.thromres.2016.06.009.
• HAIG, YLVA; Enden, Tone Rønnaug; Grøtta, Ole Jørgen; Kløw, Nils-Einar; Slagsvold, Carl Erik & Ghanima, Waleed Khalid [Vis alle 13 forfattere av denne artikkelen] (2016). Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. The Lancet Haematology. ISSN 2352-3026. 3(2), s. e64–e71. doi: 10.1016/S2352-3026(15)00248-3.
• Tinholt, Mari; Sandset, Per Morten & Iversen, Nina (2016). Polymorphisms of the coagulation system and risk of cancer. Thrombosis Research. ISSN 0049-3848. 140, s. S49–S54. doi: 10.1016/S0049-3848(16)30098-6.
• Ali, Huda Omar; Stavik, Benedicte; Myklebust, Christiane Filion; Andersen, Elisabeth; Dahm, Anders Erik A & Iversen, Nina [Vis alle 8 forfattere av denne artikkelen] (2016). Oestrogens downregulate tissue factor pathway inhibitor through oestrogen response elements in the 5′-flanking region. PLOS ONE. ISSN 1932-6203. 11(3). doi: 10.1371/journal.pone.0152114.
• Johnson, Karen C; Aragaki, Aaron; Jackson, Rebecca; Reiner, Alex P; Sandset, Per Morten & Rosing, Jan [Vis alle 14 forfattere av denne artikkelen] (2016). Tissue factor pathway inhibitor, activated protein C resistance, and risk of coronary heart disease due to combined estrogen plus progestin therapy. Arteriosclerosis, Thrombosis and Vascular Biology. ISSN 1079-5642. 36(2), s. 418–424. doi: 10.1161/ATVBAHA.115.306905.
• Stavik, Benedicte; Espada Serrano, Sandra; Cui, Xue-Yan; Iversen, Nina; Holm, Sverre & Mowinckel, Marie-Christine [Vis alle 9 forfattere av denne artikkelen] (2016). EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells. Biochimica et Biophysica Acta - Molecular Basis of Disease. ISSN 0925-4439. 1862(4), s. 670–678. doi: 10.1016/j.bbadis.2016.01.017. Vis sammendrag

  Neovascularization and hemorrhaging are evident in advanced atherosclerotic plaques due to hypoxic conditions, and mediate the accumulation of metabolic substrates, inflammatory cells, lipids, and other blood born factors inside the plaque. Tissue factor (TF) pathway inhibitor (TFPI) is mainly expressed by endothelial cells and is the endogenous inhibitor of the coagulation activator TF, which together with the downstream product thrombin can drive plaque progression and atherogenesis. We aimed to investigate the effect of hypoxic conditions on endothelial cell expression and activity of TFPI and TF that are important in coagulation initiation. Hypoxia was induced in primary human umbilical vein endothelial cells using chemicals or 1% oxygen tension, and mRNA and protein expressions were measured using qRT-PCR, ELISA, and Western blot analysis. Microscopy of fluorescence-labeled cells was used to visualize cell-associated TFPI. Cell-surface factor Xa (FXa) activity was measured using a two-stage chromogenic substrate method. We found that hypoxia reduced the TFPI mRNA and protein levels and increased the TF mRNA expression in a dose-dependent manner. The effect on TFPI was apparent on all the protein pools of TFPI, i.e., secreted TFPI, cell-surface associated TFPI, and intracellular TFPI, and seemed to be dependent upon hypoxia inducible factor-2α (HIF-2α). An increase in FXa activity was also observed on the endothelial cell surface, reflecting an increase in pro-thrombotic potential of the cells. Our findings indicate that hypoxic conditions may enhance the pro-coagulant activity of endothelial cells, which may promote atherogenesis in addition to clinical events and thus the severity of atherosclerotic disorders.

• Utne, Kristin Kornelia; Ghanima, Waleed Khalid; Foyn, Siv Lindholm; Kahn, Susan; Sandset, Per Morten & Skuterud Wik, Hilde (2016). Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome. Thrombosis and Haemostasis. ISSN 0340-6245. 115(2), s. 233–463. doi: 10.1160/TH15-04-0318. Vis sammendrag

  Post-thrombotic syndrome (PTS) is a long-term complication of deep-vein thrombosis (DVT). The Villalta scale is the recommended tool for diagnosing PTS, but requires a clinician’s assessment in addition to patient self-assessment. In the present study, we validated a self-administered tool for patient reporting of leg symptoms and signs as a mean to assess PTS. We first validated a form for patient self-reported Villalta (PRV1), then developed and validated a visually assisted form (PRV2). The validity of PRV1 and PRV2 was assessed in patients diagnosed with DVT between 2004 and 2012. Median time from DVT to inclusion was 5.1 and 3.5 years for PRV1 (n=162) and PRV2 (n=94), respectively. Patients were requested to complete the PRV form before a scheduled visit. PTS diagnosed by the original Villalta scale during the visit served as the reference method. PRV1 showed only moderate agreement for diagnosing PTS compared with the original Villalta scale (kappa agreement 0.60, 95 % CI 0.48–0.72), whereas PRV2 showed very good agreement (0.82, 95 % CI 0.71–0.94). In the validation of PRV2, PTS was diagnosed in 54 (57 %) patients according to the original Villalta scale and in 60 (64 %) by PRV2. The sensitivity of PRV2 to detect PTS was 98 % and the specificity was 83 %. We conclude that the visually assisted form for PRV is a valid and sensitive tool for diagnosing PTS. Such a tool could be applied in further clinical studies of PTS, making studies less resource demanding by reducing the need for in-person clinic visits.

• Skuterud Wik, Hilde; Jacobsen, Anne Flem; Mowinckel, Marie-Christine & Sandset, Per Morten (2016). The role of inflammation in post-thrombotic syndrome after pregnancy-related deep vein thrombosis: A population-based, cross-sectional study. Thrombosis Research. ISSN 0049-3848. 138, s. 16–21. doi: 10.1016/j.thromres.2015.12.014.
• Berntsen, Christopher Friis; Kristiansen, Annette; Akl, Elie A; Sandset, Per Morten; Jacobsen, Eva-Marie & Guyatt, Gordon [Vis alle 7 forfattere av denne artikkelen] (2016). Compression Stockings for Preventing the Postthrombotic Syndrome in Patients with Deep Vein Thrombosis. American Journal of Medicine. ISSN 0002-9343. 129(4), s. 447.e1–447.e20. doi: 10.1016/j.amjmed.2015.11.031. Vis sammendrag

  OBJECTIVE: We conducted a systematic review and meta-analysis to address benefits and harms of using elastic compression stockings after lower-extremity deep vein thrombosis. METHODS: We searched 7 electronic databases through January 15, 2015, including randomized controlled trials (RCTs)/quasi-randomized trials reporting on elastic compression stocking efficacy on postthrombotic syndrome incidence, recurrent venous thromboembolism, mortality, and acute pain after deep vein thrombosis. Two reviewers independently screened records, extracted data, assessed risk of bias, and assessed confidence in effect estimates using Grading of Recommendations Assessment, Development, and Evaluation methodology. We applied random-effects meta-analysis models. RESULTS: We included 5 RCTs (n = 1418) reporting on postthrombotic syndrome. The hazard ratio (HR) for postthrombotic syndrome with elastic compression stockings was 0.69 (95% confidence interval [CI], 0.47-1.02). We have very low confidence in this estimate due to heterogeneity and inclusion of unblinded studies at high risk of bias. Excluding high risk of bias studies, a single large RCT at low risk of bias provided moderate-quality evidence of no effect on postthrombotic syndrome (HR 1.00; 95% CI, 0.81-1.24). Moderate-quality evidence including all 5 studies suggests no effect of elastic compression stockings on recurrent venous thromboembolism (relative risk [RR] 0.88; 95% CI, 0.63-1.24) or mortality (RR 1.00; 95% CI, 0.73-1.37, 5 studies). Moderate-quality evidence from one large RCT does not suggest effect on acute pain after deep vein thrombosis. CONCLUSIONS: The highest-quality evidence available suggests no effect of elastic compression stockings on postthrombotic syndrome or pain relief, from a single large RCT. However, results for preventing postthrombotic syndrome differ substantially across studies, and future guideline updates should reflect uncertainty about treatment effects. Elastic compression stockings are unlikely to prevent death or recurrent venous thromboembolism.

• Cui, Xue-Yan; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A; Kanse, Sandip & Jin, Yang [Vis alle 11 forfattere av denne artikkelen] (2016). Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 14(2), s. 387–396. doi: 10.1111/jth.13206.
• Ali, Huda Omar; Arroyo, Ana Belen V.; Conejero, RG; Stavik, Benedicte; Iversen, Nina & Sandset, Per Morten [Vis alle 8 forfattere av denne artikkelen] (2015). Novel regulation of TFPI expression by oestrogens in breast cancer cells thorugh miroRNAs. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13, s. 263–264.
• Ali, Huda Omar; Stavik, Benedicte; Myklebust, Christiane Filion; Andersen, Elisabeth; Iversen, Nina & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2015). Oestrogens regulate TFPI expression through oestrogen response elements in TFPI 5’-flanking region. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13, s. 307–307.
• Cui, Xueyan; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A; Kanse, Sandip & Seidl, Sebastian [Vis alle 11 forfattere av denne artikkelen] (2015). Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer cell lines and tissues. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13, s. 303–303.
• Andresen, Marianne Seierstad; Ali, Huda Omar; Iversen, Nina; Stavik, Benedicte; Myklebust, Christiane Filion & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2015). Estrogens upregulate TFPI-2 expression in MCF-7 cells probably through demethylation. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13, s. 306–306.
• Chollett, Maria Eugenia; Skarpen, Ellen; Iversen, Nina; Sandset, Per Morten & Skretting, Grethe (2015). The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells through the GRASP55 pathway. Cell & Bioscience. ISSN 2045-3701. doi: 10.1186/s13578-015-0048-4.
• Iversen, Per Ole; Dahm, Anders Erik A; Skretting, Grethe; Mowinckel, Marie-Christine; Haslestad, Annicke Stranda & Østerud, Bjarne [Vis alle 8 forfattere av denne artikkelen] (2015). Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study. Thrombosis and Haemostasis. ISSN 0340-6245. 114(5), s. 964–968. doi: 10.1160/TH15-05-0396.
• Comerota, Anthony J.; Sandset, Per Morten; Konstantinides, Stavros; De Graaf, Rick; Wakefield, Thomas W. & Arnoldussen, Carsten W.K.P. [Vis alle 13 forfattere av denne artikkelen] (2015). Theme 4: Invasive management of (recurrent) VTE and PTS. Thrombosis Research. ISSN 0049-3848. 136, s. S19–S25. doi: 10.1016/j.thromres.2015.07.037.
• Eckman, Mark H.; Alonso-Coello, Pablo; Guyatt, Gordon H.; Ebrahim, Shanil; Tikkinen, Kari A.O. & Lopes, Luciane Cruz [Vis alle 17 forfattere av denne artikkelen] (2015). Women's values and preferences for thromboprophylaxis during pregnancy: A comparison of direct-choice and decision analysis using patient specific utilities. Thrombosis Research. ISSN 0049-3848. 136(2), s. 341–347. doi: 10.1016/j.thromres.2015.05.020.
• Sandset, Else Charlotte; Jusufovic, Mirza; Sandset, Per Morten; Bath, Philip M.W. & Berge, Eivind (2015). Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. Stroke. ISSN 0039-2499. 46(3), s. 877–879. doi: 10.1161/STROKEAHA.114.008512.
• Stiksrud, Birgitte; Nowak, Piotr; Nwosu, Felix Chinweije; Kvale, Dag; Thalme, Anders & Sönnerborg, Anders [Vis alle 15 forfattere av denne artikkelen] (2015). Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART. Journal of Acquired Immune Deficiency Syndromes. ISSN 1525-4135. 70(4), s. 329–337. doi: 10.1097/QAI.0000000000000784.
• Craigie, Samantha; Tsui, Johnson F.; Agarwal, Arnav; Sandset, Per Morten; Guyatt, Gordon H. & Tikkinen, Kari A. O. (2015). Adherence to mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis. Thrombosis Research. ISSN 0049-3848. 136(4), s. 723–726. doi: 10.1016/j.thromres.2015.06.023.
• Tinholt, Mari; Vollan, Hans Kristian Moen; Sahlberg, Kristine Kleivi; Jernström, Sandra Johanna; Kaveh, Fatemeh & Lingjærde, Ole Christian [Vis alle 12 forfattere av denne artikkelen] (2015). Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. Breast Cancer Research. ISSN 1465-5411. 17(44), s. 1–15. doi: 10.1186/s13058-015-0548-5.
• Beitland, Sigrid; Sandven, Irene; Kjærvik, Lill-Kristin Krohn; Sandset, Per Morten; Sunde, Kjetil & Eken, Torsten (2015). Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine. ISSN 0342-4642. 41(7), s. 1209–1219. doi: 10.1007/s00134-015-3840-z.
• Tinholt, Mari; Stavik, Benedicte; Louch, William Edward; Carlson, Cathrine Rein; Sletten, Marit & Ruf, Wolfram [Vis alle 9 forfattere av denne artikkelen] (2015). Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells. PLOS ONE. ISSN 1932-6203. 10(1). doi: 10.1371/journal.pone.0117404.
• Pitkänen, Hanna; Jouppila, Annukka; Mowinckel, Marie-Christine; Lemponen, Marja; Patiwael, Sanne & Sandset, Per Morten [Vis alle 8 forfattere av denne artikkelen] (2015). Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. Thrombosis Research. ISSN 0049-3848. 135(1), s. 167–174. doi: 10.1016/j.thromres.2014.10.020.
• Kostovski, Emil; Dahm, Anders Erik A; Mowinckel, Marie-Christine; Stranda, Annicke; Skretting, Grethe & Østerud, Bjarne [Vis alle 8 forfattere av denne artikkelen] (2015). Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled cross-over study of melatonin. Spinal Cord. ISSN 1362-4393. 53, s. 285–290. doi: 10.1038/sc.2014.243. Fulltekst i vitenarkiv
• Subramaniam, Saravanan; Thielmann, Ina; Morowski, Martina; Pragst, Ingo; Sandset, Per Morten & Nieswandt, Bernhard [Vis alle 8 forfattere av denne artikkelen] (2015). Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP). Thrombosis and Haemostasis. ISSN 0340-6245. 113(4), s. 870–880. doi: 10.1160/TH14-06-0519.
• Cui, Xueyan; Skretting, Grethe; Dahm, Anders Erik A; Stavik, Benedicte; Iversen, Nina & Sandset, Per Morten (2014). Hypoxia contributes to procoagulant activity of breast cancer cells. Haematologica. ISSN 0390-6078. 99, s. 475–475.
• Ali, Huda Omar; Stavik, Benedicte; Andersen, Elisabeth; Myklebust, Christiane Filion; Iversen, Nina & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2014). Oestrogens downregulate TFPI expression through direct interaction and inhibition of its promoter activity. Thrombosis Research. ISSN 0049-3848. 133.
• Stavik, Benedicte; Halvorsen, Bente; Iversen, Nina; Dahl, Tuva Børresdatter; Sandset, Per Morten & Skretting, Grethe (2014). Hypoxic conditions regulate the expression and activity of coagulation factors important in atherothrombosis. Arteriosclerosis, Thrombosis and Vascular Biology. ISSN 1079-5642. 34.
• Tikkinen, Kari A. O.; Agarwal, Arnav; Craigie, Samantha; Cartwright, Rufus; Gould, Michael K. & Haukka, Jari [Vis alle 12 forfattere av denne artikkelen] (2014). Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): Introduction and methodology. Systematic Reviews. ISSN 2046-4053. 3(1). doi: 10.1186/2046-4053-3-150.
• Tinholt, Mari; Viken, Marte K; Dahm, Anders Erik A; Vollan, Hans Kristian Moen; Sahlberg, Kristine Kleivi & Garred, Øystein [Vis alle 16 forfattere av denne artikkelen] (2014). Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer. ISSN 1471-2407. 14. doi: 10.1186/1471-2407-14-845.
• HAIG, YLVA; Enden, Tone Rønnaug; Slagsvold, Carl Erik; Sandvik, Leiv; Sandset, Per Morten & Klow, Nils-Einar (2014). Residual rates of reflux and obstruction and their correlation to post-thrombotic syndrome in a randomized study on catheter-directed thrombolysis for deep vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders (JVS-VL). ISSN 2213-333X. 2(2), s. 123–130. doi: 10.1016/j.jvsv.2013.10.054.
• Kristiansen, Annette; Brandt, Linn; Agoritsas, Thomas; Akl, Elie A.; Berge, Eivind & Bondi, Johan Fridtjof [Vis alle 19 forfattere av denne artikkelen] (2014). Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process. Chest. ISSN 0012-3692. 146(3), s. 727–734. doi: 10.1378/chest.13-2828. Vis sammendrag

  BACKGROUND: Adaptation of guidelines for use at the national or local level can facilitate their implementation. We developed and evaluated an adaptation process in adherence with standards for trustworthy guidelines and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, aiming for efficiency and transparency. This article is the first in a series describing our adaptation of Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for a Norwegian setting. METHODS: Informed by the ADAPTE framework, we developed a five-step adaptation process customized to guidelines developed using GRADE: (1) planning, (2) initial assessment of the recommendations, (3) modification, (4) publication, and (5) evaluation. We developed a taxonomy for describing how and why recommendations from the parent guideline were modified and applied a mixed-methods case study design for evaluation of the process. RESULTS: We published the adapted guideline in November 2013 in a novel multilayered format. The taxonomy for adaptation facilitated transparency of the modification process for both the guideline developers and the end users. We excluded 30 and modified 131 of the 333 original recommendations according to the taxonomy and developed eight new recommendations. Unforeseen obstacles related to acquiring a licensing agreement and procuring a publisher resulted in a 9-month delay. We propose modifications of the adaptation process to overcome these obstacles in the future. CONCLUSIONS: This case study demonstrates the feasibility of a novel guideline adaptation process. Replication is needed to further validate the usefulness of the process in increasing the organizational and methodologic efficiency of guideline adaptation.

• Ali, Huda Omar; Stavik, Benedicte; Dørum, Elisabeth; Iversen, Nina; Sandset, Per Morten & Skretting, Grethe (2014). Oestrogen induced downregulation of TFPI expression is mediated by ERα. Thrombosis Research. ISSN 0049-3848. 134(1), s. 138–143. doi: 10.1016/j.thromres.2014.04.004.
• Vartdal, Trond; Fetveit, Arne; Kristiansen, Annette; Brandt, Linn; Halvorsen, Sigrun & Berge, Eivind [Vis alle 9 forfattere av denne artikkelen] (2014). Antitrombotisk behandling og profylakse: - ny generasjon retningslinjer for allmennleger. Utposten. ISSN 0800-5680. 3, s. 41–43.
• Tavoly, Mazdak; Jelsness-Jørgensen, Lars-Petter; Skuterud Wik, Hilde; Roaldsnes, Christina; Sandset, Per Morten & Ghanima, Waleed Khalid (2014). Quality of life after pulmonary embolism: first cross-cultural evaluation of the pulmonary embolism quality-of-life (PEmb-QoL) questionnaire in a Norwegian cohort. Quality of Life Research. ISSN 0962-9343. 24(2), s. 417–425. doi: 10.1007/s11136-014-0779-4.
• Narverud, Ingunn; Iversen, Per Ole; Aukrust, Pål; Halvorsen, Bente ; Ueland, Thor & Johansen, Siril Garmannvik [Vis alle 12 forfattere av denne artikkelen] (2013). Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. Thrombosis Research. ISSN 0049-3848. 131(2), s. 178–182. doi: 10.1016/j.thromres.2012.11.008.
• HELGADOTTIR, LINDA BJØRK; Turowski, Gitta Erika; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Sandset, Per Morten & Roald, Borghild [Vis alle 7 forfattere av denne artikkelen] (2013). Classification of stillbirths and risk factors by cause of death a case-control study. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 92(3), s. 325–333. doi: 10.1111/aogs.12044.
• Ali, Huda Omar; Stavik, Benedicte; Andersen, Elisabeth; Iversen, Nina; Sandset, Per Morten & Skretting, Grethe (2013). Estrogens downregulate TFPI expression in breast cancer cells. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 11, s. 723–723.
• Cui, Xueyan; Stavik, Benedicte; Myklebust, Christiane Filion; Andresen, Marianne Seierstad; Andersen, Elisabeth & Iversen, Nina [Vis alle 8 forfattere av denne artikkelen] (2013). Sodium butyrate induces TFPI-mediated apoptosis through AKT/mTOR pathway. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 11, s. 478–478.
• Tinholt, Mari; Stavik, Benedicte; Wiiger, Merete Thune; Louch, William Edward; Sletten, Marit & Skretting, Grethe [Vis alle 9 forfattere av denne artikkelen] (2013). TFPIa and TFPIb inhibit tumor growth and associate with invasive tumor phenotypes. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 11, s. 432–432.
• Skretting, Grethe; Myklebust, Christiane Filion; Andersen, Elisabeth; Stavik, Benedicte; Iversen, Nina & Sandset, Per Morten (2013). Increased expression of TFPI by NaBut is due to involvement of F changes in the acetylation pattern of the TFPI promoter. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 11, s. 432–433.
• Enden, Tone Rønnaug; Klow, Nils-Einar & Sandset, Per Morten (2013). Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis. Patient Related Outcome Measures. ISSN 1179-271X. 4, s. 55–59. doi: 10.2147/PROM.S47233.
• Enden, Tone Rønnaug; Skuterud Wik, Hilde; Kvam, Ann Kristin; Klow, Nils-Einar & Sandset, Per Morten (2013). Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open. ISSN 2044-6055. 3(8). doi: 10.1136/bmjopen-2013-002984.
• Ghanima, Waleed Khalid; Atar, Dan & Sandset, Per Morten (2013). Nye perorale antikoagulasjonsmidler – en oversikt. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(18), s. 1940–1945. doi: 10.4045/tidsskr.12.1111.
• Gravensteen, Ida Kathrine; HELGADOTTIR, LINDA BJØRK; Jacobsen, Eva-Marie; Rådestad, Ingela; Sandset, Per Morten & Ekeberg, Øivind (2013). Women's experiences in relation to stillbirth and risk factors for long-term post-traumatic stress symptoms: a retrospective study. BMJ Open. ISSN 2044-6055. 3(10). doi: 10.1136/bmjopen-2013-003323. Fulltekst i vitenarkiv
• Aamodt, Anne Hege ; Sandset, Per Morten; Atar, Dan; Tveit, Arnljot & Russell, David (2013). Atrieflimmer og hjerneslag. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(14), s. 1453–1457. doi: 10.4045/tidsskr.12.0850.
• Cui, Xue-Yan; Skretting, Grethe; Jing, Ying; Sun, Hui; Sandset, Per Morten & Sun, Ling (2013). Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells, Molecules & Diseases. ISSN 1079-9796. 51(3), s. 177–184. doi: 10.1016/j.bcmd.2013.05.003.
• Enden, Tone Rønnaug; Resch, S.; White, Christopher; Skuterud Wik, Hilde; Klow, Nils-Einar & Sandset, Per Morten (2013). Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 11(6), s. 1032–1042. doi: 10.1111/jth.12184.
• Whiteley, William N.; Adams, Harold P.; Bath, Philip M.W.; Berge, Eivind; Sandset, Per Morten & Dennis, Martin [Vis alle 9 forfattere av denne artikkelen] (2013). Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurology. ISSN 1474-4422. 12(6), s. 539–545. doi: 10.1016/S1474-4422(13)70079-6.
• Skuterud Wik, Hilde; Jacobsen, Anne Flem; Fagerland, Morten; Sandvik, Leiv & Sandset, Per Morten (2013). Long-term mortality and incidence of cancer after pregnancy-related venous thrombosis: Results of a population-based cohort study. Thrombosis Research. ISSN 0049-3848. 131(6), s. 497–501. doi: 10.1016/j.thromres.2013.04.035.
• Raps, M; Helmerhorst, FM; Fleischer, K; Dahm, Anders Erik A; Rosendaal, FR & Rosing, J [Vis alle 9 forfattere av denne artikkelen] (2013). The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thrombosis and Haemostasis. ISSN 0340-6245. 109(4), s. 606–613. doi: 10.1160/TH12-10-0771.
• Stavik, Benedicte; Tinholt, Mari; Sletten, Marit; Skretting, Grethe; Sandset, Per Morten & Iversen, Nina (2013). TFPI alpha and TFPI beta are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. Journal of Hematology & Oncology. ISSN 1756-8722. 6. doi: 10.1186/1756-8722-6-5.
• Sandset, Per Morten (2013). Mechanisms of hormonal therapy related thrombosis. Thrombosis Research. ISSN 0049-3848. 131, s. S4–S7. doi: 10.1016/s0049-3848(13)70009-4.
• HAIG, YLVA; Enden, Tone Rønnaug; Slagsvold, Carl Erik; Sandvik, Leiv; Sandset, Per Morten & Klow, Nils-Einar (2013). Determinants of Early and Long-term Efficacy of Catheter-directed Thrombolysis in Proximal Deep Vein Thrombosis. Journal of Vascular and Interventional Radiology. ISSN 1051-0443. 24(1), s. 17–24. doi: 10.1016/j.jvir.2012.09.023.
• Skretting, Grethe; Iversen, Nina; Myklebust, Christiane Filion; Dahm, Anders Erik A & Sandset, Per Morten (2012). Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF-kappa B and apoptosis mediated by a caspase-3 independent pathway. Molecular Biology Reports. ISSN 0301-4851. 39(12), s. 10089–10096. doi: 10.1007/s11033-012-1882-7.
• Stavik, Benedicte; Skretting, Grethe; Olstad, Ole Kristoffer; Sletten, Marit; Vigeland, Magnus Dehli & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2012). TFPI Alpha and Beta Regulate mRNAs and microRNAs Involved in Cancer Biology and in the Immune System in Breast Cancer Cells. PLOS ONE. ISSN 1932-6203. 7(10). doi: 10.1371/journal.pone.0047184.
• Jacobsen, Anne Flem & Sandset, Per Morten (2012). Venous thromboembolism associated with pregnancy and hormonal therapy. Baillière's Best Practice & Research: Clinical Haematology. ISSN 1521-6926. 25(3), s. 319–332. doi: 10.1016/j.beha.2012.07.006.
• Skuterud Wik, Hilde; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2012). Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 10(5), s. 840–847. doi: 10.1111/j.1538-7836.2012.04690.x.
• Gravensteen, Ida Kathrine; HELGADOTTIR, LINDA BJØRK; Jacobsen, Eva-Marie; Sandset, Per Morten & Ekeberg, Øivind (2012). Long-term impact of intrauterine fetal death on quality of life and depression: a case-control study. BMC Pregnancy and Childbirth. ISSN 1471-2393. 12(43). doi: 10.1186/1471-2393-12-43.
• Dahm, Anders Erik A; Bezemer, Irene D; Bergrem, Astrid; Jacobsen, Anne Flem; Jacobsen, Eva-Marie & Skretting, Grethe [Vis alle 8 forfattere av denne artikkelen] (2012). Candidate gene polymorphisms and the risk for pregnancy-related venous thrombosis. British Journal of Haematology. ISSN 0007-1048. 157(6), s. 753–761. doi: 10.1111/j.1365-2141.2012.09121.x.
• Sandset, Per Morten (2012). CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer. Thrombosis Research. ISSN 0049-3848. 129, s. S97–S100. doi: 10.1016/S0049-3848(12)70026-9.
• HELGADOTTIR, LINDA BJØRK; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Sandset, Per Morten & Jacobsen, Eva-Marie (2012). The association of antiphospholipid antibodies with intrauterine fetal death: A case-control study. Thrombosis Research. ISSN 0049-3848. 130(1), s. 32–37. doi: 10.1016/j.thromres.2011.11.029.
• Dahm, Anders Erik A; Eilertsen, Anette Løken; Goeman, Jelle; Olstad, Ole Kristoffer; Øvstebø, Reidun & Kierulf, Peter [Vis alle 9 forfattere av denne artikkelen] (2012). A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thrombosis Research. ISSN 0049-3848. 130(1), s. 45–51. doi: 10.1016/j.thromres.2011.12.009.
• Alatri, Adriano; Armstrong, Anna-Elina; Greinacher, Andreas; Koster, Andreas; Kozek-Langenecker, Sibylle A. & Lancé, Marcus D. [Vis alle 11 forfattere av denne artikkelen] (2012). Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - A European Perspective. Thrombosis Research. ISSN 0049-3848. 129(4), s. 426–433. doi: 10.1016/j.thromres.2011.11.041.
• Enden, Tone Rønnaug; HAIG, YLVA; Klow, Nils-Einar; Slagsvold, Carl Erik; Sandvik, Leiv & Ghanima, Waleed Khalid [Vis alle 12 forfattere av denne artikkelen] (2012). Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. The Lancet. ISSN 0140-6736. 379(9810), s. 31–38. doi: 10.1016/S0140-6736(11)61753-4.
• Rossouw, Jacques E; Johnson, Karen C; Pettinger, Mary; Cushman, Mary; Sandset, Per Morten & Kuller, Lewis [Vis alle 14 forfattere av denne artikkelen] (2012). Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy. Stroke. ISSN 0039-2499. 43(4), s. 952–957. doi: 10.1161/STROKEAHA.111.643072.
• Skuterud Wik, Hilde; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2012). Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case–control study. BMJ Open. ISSN 2044-6055. 2. doi: 10.1136/bmjopen-2012-002048.
• Bergrem, Astrid; Dahm, Anders Erik A; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2012). Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism A population-based case-control study. Thrombosis and Haemostasis. ISSN 0340-6245. 108(6), s. 1165–1171. doi: 10.1160/TH12-05-0350.
• HELGADOTTIR, LINDA BJØRK; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Sandset, Per Morten & Jacobsen, Eva-Marie (2011). The association of inherited thrombophilia and intrauterine fetal death: a case-control study. Blood Coagulation and Fibrinolysis. ISSN 0957-5235. 22(8), s. 651–656. doi: 10.1097/MBC.0b013e32834a614c.
• Skuterud Wik, Hilde; Enden, Tone Rønnaug; Jacobsen, Anne Flem & Sandset, Per Morten (2011). Long-term quality of life after pregnancy-related deep vein thrombosis and the influence of socioeconomic factors and comorbidity. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 9(10), s. 1931–1936. doi: 10.1111/j.1538-7836.2011.04468.x.
• Tjeldhorn, Lena; Iversen, Nina; Sandvig, Kirsten; Bergan, Jonas; Sandset, Per Morten & Skretting, Grethe (2011). Protein C Mutation (A267T) Results in ER Retention and Unfolded Protein Response Activation. PLOS ONE. ISSN 1932-6203. 6(8). doi: 10.1371/journal.pone.0024009.
• Stavik, Benedicte; Skretting, Grethe; Åsheim, Hans-Christian; Tinholt, Mari; Zernichow, Lillian & Sletten, Marit [Vis alle 8 forfattere av denne artikkelen] (2011). Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer. ISSN 1471-2407. 11. doi: 10.1186/1471-2407-11-357.
• Kristiansen, Marianne; Narum, Sigrid; Lygren, Idar; Seljeflot, Ingebjørg; Sandset, Per Morten & Siebke, Anne-Marie [Vis alle 9 forfattere av denne artikkelen] (2011). Reduced Platelet Function and Role of Drugs in Acute Gastrointestinal Bleeding. Basic & Clinical Pharmacology & Toxicology. ISSN 1742-7835. 108(3), s. 194–201. doi: 10.1111/j.1742-7843.2010.00643.x.
• Pettersen, Frank Olav; Torheim, Eirik A.; Dahm, Anders Erik A; Aaberge, Ingeborg Sundsvalen; Lind, Andreas & Holm, Malin [Vis alle 10 forfattere av denne artikkelen] (2011). An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: Downregulated immune activation and improved T Cell-dependent vaccine responses. Journal of Virology. ISSN 0022-538X. 85(13), s. 6557–6566. doi: 10.1128/JVI.00073-11.
• Bergrem, Astrid; Dahm, Anders Erik A; Jacobsen, Anne Flem; Mowinckel, Marie-Christine; Sandvik, Leiv & Sandset, Per Morten (2011). Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. British Journal of Haematology. ISSN 0007-1048. 154(2), s. 241–247. doi: 10.1111/j.1365-2141.2011.08712.x. Vis sammendrag

  Resistance to activated protein C (aPC) is most commonly due to the F5 rs6025 (factor V Leiden) polymorphism, which increases the risk of venous thrombosis. In the present population-based study of 313 cases and 353 controls, we investigated whether reduced sensitivity to aPC was associated with a history of pregnancy-related venous thrombosis. Calibrated automated thrombography was used to determine the sensitivity to aPC, and normalized aPC sensitivity ratio (n-aPC-sr) was calculated. Pregnant women and women using oral contraceptives and/or anticoagulants were excluded due to the effect on the n-aPC-sr. In women without the F5 rs6025 polymorphism, free tissue factor pathway inhibitor (TFPI), free protein S and protein C activity were associated with n-aPC-sr. Unadjusted odds ratio for venous thrombosis for women with n-aPC-sr in the 4th quartile as compared with n-aPC-sr below the 4th quartile was 2·4 (95% confidence interval 1·7-3·6). Adjusting for free protein S, free TFPI and age did not influence the odds ratios. Also in carriers of the F5 rs6025 polymorphism the risk for venous thrombosis was increased for women with higher n-aPC-sr. Our findings substantiate the importance of the aPC resistant phenotype as a risk factor for pregnancy-related venous thrombosis.

• HELGADOTTIR, LINDA BJØRK; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Sandset, Per Morten & Jacobsen, Eva-Marie (2011). Incidence and risk factors of fetal death in Norway: a case-control study. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 90(4), s. 390–397. doi: 10.1111/j.1600-0412.2011.01079.x. Vis sammendrag

  Objective. To estimate incidence and risk factors for intrauterine fetal death (IUFD) in a Norwegian study-population applying two different control groups. Design. Case-control study. Setting. Two university hospitals in Oslo, Norway, January 1990 through December 2003. Sample. The cases: 377 women with IUFD. Controls: 1) all women delivering at the study-hospitals in the period (facility-based), and 2) 1 215 women with live births at one study-hospital in the period (selected). Methods. Information from cases and selected controls was collected from medical records. Data on facility-based controls were provided by the Medical Birth Registry of Norway. Data were analyzed using chi-squared test and logistic regression. Main outcome measures. Incidence of IUFD and adjusted odds ratios of risk factors. Results. The incidence was 4.1/1 000 deliveries. Small-for-gestational age (SGA) and placental abruption were the strongest risk factors for IUFD. Hypertensive disorders were of low risk if not associated with SGA. Low to moderate risk factors were pre-pregnancy diabetes mellitus, thyroid disease, placenta previa, gestational diabetes, smoking and twin pregnancy. Advanced maternal age was significant when compared with facility-based controls. Risk estimates pointed in the same direction independent of control-group. Hypertension appeared overestimated when using facility-based controls, whereas advanced age was underestimated in the analysis among selected controls. Conclusion. SGA has a strong association with IUFD, and the risk of hypertensive disorders is mediated through SGA. The other risk factors, except placental abruption, are of low prevalence and of limited importance in the prevention of a relatively low incidence, although dramatic, event like IUFD.

• Kostovski, Emil; Dahm, Anders Erik A; Iversen, Nina; Hjeltnes, Nils; Østerud, Bjarne & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2011). Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagulation and Fibrinolysis. ISSN 0957-5235. 22(4), s. 254–259. doi: 10.1097/MBC.0b013e3283442ce2. Vis sammendrag

  We previously found an association between the circadian variation of free tissue factor pathway inhibitor (TFPI) and melatonin in able-bodied males and in men with complete cervical spinal cord injuries. We therefore examined whether melatonin modifies production and/or secretion of TFPI in endothelial cells. We sampled supernatants from cultures of primary human umbilical vein endothelial cells (HUVECs) and of human coronary artery endothelial cells (HCAECs), that had been exposed to varying doses (0-300 pg/ml) of melatonin for 0.5-24 h. We then measured the protein concentrations of free TFPI, tissue factor and plasminogen activator inhibitor type 1 (PAI-1). We also measured endothelial TFPI, tissue factor and PAI-1 transcripts using quantitative real-time PCR. Melatonin dose dependently increased free TFPI levels about 25-30-fold in supernatants of both HUVEC and HCAEC, and independent of incubation duration. In contrast, TF and PAI-1 remained unaltered upon increasing doses of melatonin. Neither TFPI mRNAs nor tissue factor mRNAs nor PAI-1-mRNAs were changed in cell cultures added melatonin. The ratio of free TFPI in cell supernatants to free TFPI in cell lysates about doubled upon addition of melatonin, indicating that melatonin increased release from intracellular storages of free TFPI or from membrane-bound free TFPI. Our data indicate that melatonin stimulates vascular endothelial cells to secrete TFPI without altering transcription of the TFPI gene. If melatonin increases TFPI release in a similar fashion in vivo as in vitro, this could have potential clinical implications in both prophylaxis and treatment of thromboembolic events.

• Lassila, R; Antovic, Jovan P; Armstrong, Elina; Baghaei, Fariba; Dalsgaard-Nielsen, Jørn & Hilllarp, Andreas [Vis alle 11 forfattere av denne artikkelen] (2011). Practical viewpoints on the diagnosis and management of heparin induced thrombocytopenia. Seminars in Thrombosis and Hemostasis. ISSN 0094-6176. 37(3), s. 328–335. doi: 10.1055/s-0031-1274516. Vis sammendrag

  Heparin-induced thrombocytopenia (HIT, type II) is an immune-mediated disorder due to antibodies formed against heparin-platelet factor 4 complexes, usually appearing at days 5 to 14 after initiation of heparin. It is important to recognize HIT because heparin prophylaxis or treatment paradoxically associates with new venous and/or arterial thrombosis. Early clinical suspicion and diagnosis together with proper pharmacotherapy and close laboratory monitoring are the cornerstones for successful management. This includes monitoring of Thrombocytopenia, its Timing to heparin administration, appearance of new Thrombosis or resistance to treatment, and differential diagnosis by exclusion of o Ther causes (the 4T's). Specific attention should be paid to the absence or presence of thrombosis and to tailoring thromboprophylaxis or anticoagulant therapy with a nonheparin alternative. Even in the absence of HIT-associated thrombosis, an active policy for prolonged thromboprophylaxis is demanded. Rapid and reliable assays should be developed for diagnosis and anticoagulation monitoring to secure safe management with nonheparins. Semiquantitative testing for on-call hours should be available and later confirmed as clinically needed. Alternative therapeutic options are available, but because their use is infrequent, experienced coagulation treatment centers should provide guidance in the treatment and in laboratory monitoring. Most of the evidence in HIT is grade IC, and thus the best evidence is provided by clinical experience. New anticoagulants and platelet inhibitors may offer future alternatives in the management of HIT, but the current treatment options provide the best experience and benefit. The joint clinical and laboratory guidelines provided in this article along with two practical case scenarios were prepared by a Nordic expert panel. They will be valuable for hematologists and colleagues who do not routinely encounter HIT.

• Krarup, Lars-Henrik; Sandset, Else Charlotte; Sandset, Per Morten & Berg, Eivind (2011). D-dimer levels and stroke progression in patients with acute ischemic stroke and atrial fibrillation. Acta Neurologica Scandinavica. ISSN 0001-6314. 124(1), s. 40–44. doi: 10.1111/j.1600-0404.2010.01409.x. Vis sammendrag

  Background –  Patients with acute ischemic stroke and atrial fibrillation are at increased risk of stroke progression and recurrence. We sought to assess whether D-dimer and other markers of hemostatic activation could predict these adverse events in such patients. Method –  Blood samples were obtained from patients included in the Heparin in Acute Embolic Stroke Trial. Stroke progression was defined as a ≥3-point worsening on the Scandinavian Stroke Scale during the first 48 h after randomization. Blood samples were analyzed for D-dimer, prothrombin fragment 1 + 2, soluble fibrin monomer, and C-reactive protein. Results –  A total of 382 patients were included in the analyses. Levels of D-dimer and other markers of hemostatic activation were not significantly higher in patients with stroke progression than in other patients (D-dimer median values: 1025 ng/ml vs 970 ng/ml, P = 0.73). The same was true for recurrent stroke (D-dimer: 720 ng/ml vs 973 ng/ml, P = 0.96), and the combined endpoint of stroke progression, recurrent stroke, and death (D-dimer: 991 ng/ml vs 970 ng/ml, P = 0.91). Multivariable analyses did not alter the results. Conclusion –  D-dimer and other markers of hemostatic activation were not associated with stroke progression, recurrent stroke, or death in patients with acute ischemic stroke and atrial fibrillation.

• Stavik, Benedicte; Skretting, Grethe; Sletten, Marit; Olstad, Ole Kristoffer; Sandset, Per Morten & Iversen, Nina (2011). Stable overexpression of TFPI in breast cancer cells changes the expression of mRNAs and microRNAs involved in immune response and cancer development. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 9, s. 724–724.
• Kristiansen, Marianne; Narum, Sigrid; Lygren, Idar; Seljeflot, Ingebjørg; Johansen, Per Wiik & Sandset, Per Morten [Vis alle 9 forfattere av denne artikkelen] (2010). Reduced platelet function and role of drugs in acute gastrointestinal bleeding. Basic & Clinical Pharmacology & Toxicology. ISSN 1742-7835. doi: 10.1111/j.1742-7843.2010.00643.x.
• Sandset, Per Morten (2010). Utredning av arvelig trombofili anno 2010. Indremedisineren. ISSN 1891-1617. 2, s. 12–14.
• Sandset, Per Morten (2010). Immunobiology of Heparin-Induced Thrombocytopenia. Current Topics in Microbiology and Immunology. ISSN 0070-217X. 341, s. 193–202. doi: 10.1007/82_2010_17. Vis sammendrag

  Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening adverse drug reaction that may develop in certain patients exposed to heparin and is caused by antibodies with specificity for chemokine CXCL4 (formerly known as platelet factor 4)/heparin complexes. Rapid diagnosis and intervention is key to prevent severe thrombotic complications. The immunobiology of HIT is atypical as the immune reaction most often involves rapid generation of immunoglobulin class G within 5-14 days after heparin exposure, and apparently lacks memory as patients may be reexposed to heparin. This report reviews clinical presentation, diagnostic issues, and immunobiology of HIT.

• Iversen, Per Ole & Sandset, Per Morten (2010). T4 Blodsykdommer. I Fjeldstad, Trygve (Red.), Norsk legemiddelhåndbok for helsepersonell 2010. Foreningen for utgivelse av norsk legemiddelhåndbok. ISSN 9788290732108. s. 167–194.
• Iversen, Per Ole & Sandset, Per Morten (2010). L4 Legemidler ved blodsykdommer. I Fjeldstad, Trygve (Red.), Norsk legemiddelhåndbok for helsepersonell 2010. Foreningen for utgivelse av norsk legemiddelhåndbok. ISSN 9788290732108. s. 903–942.
• Sandset, Per Morten (2010). Turnuslegeboka 2010. I Aabakken, Lars & Bendz, Bjørn (Red.), Turnuslegeboka 2010. Legeforlaget. ISSN 978-82-92934-05-0. s. 193–208.
• Tjeldhorn, Lena; Sandset, Per Morten; Haugbro, Kaia Kristine & Skretting, Grethe (2010). Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis. Thrombosis Research. ISSN 0049-3848. 125(3), s. 230–234. doi: 10.1016/j.thromres.2009.05.013. Vis sammendrag

  INTRODUCTION: Protein C (PC) is a key anticoagulant that regulates hemostasis, and inherited deficiency of PC is an established risk factor for venous thrombosis (VT). The factor V Leiden mutation causing activated PC (APC) resistance is an additional risk factor for VT. Reduced PC levels in the circulation and/or APC resistance do not necessarily lead to thrombotic disease. In the present study we describe and characterize an ethnic Lebanese family in which individuals with reduced PC levels and APC resistance have various clinical symptoms. METHODS: PC activity and antigen levels and APC resistance in the family members were quantified with commercial kits. Sequencing of PC DNA and mRNA was performed with BigDye Terminator Cycle Sequencing kit on the ABI 3730 Genetic Analyzer. RESULTS: PC antigen and anticoagulant activity in the plasma of the proband and family members ranged from 9% to 69% and 3% to 63%, respectively, compared to levels measured in pooled normal plasma. Sequencing analysis of the PC gene of family members revealed that they were either homozygous or heterozygous for the Ala267Thr mutation. In addition, three of them exhibited APC resistance. None of the family members, except the proband, have had a history of VT despite that two of them have two genetic risk factors for thrombosis.

• Jacobsen, Anne Flem; Dahm, Anders Erik A; Bergrem, Astrid; Jacobsen, Eva-Marie & Sandset, Per Morten (2010). Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 8(11), s. 2443–2449. doi: 10.1111/j.1538-7836.2010.04038.x. Vis sammendrag

  Background Pregnancy is associated with a ten-fold increased risk of venous thrombosis (VT) with different risk profiles for the ante- and postnatal periods. The purpose of this study was to assess the risk of pregnancy-related VT associated with the factor V Leiden and the prothrombin gene G20210A polymorphisms. Materials and Methods The study comprised 377155 women with 613232 pregnancies at 18 Norwegian hospitals from 1 January 1990 to 31 December 2003. Of total 559 cases with a validated first lifetime diagnosis of VT in pregnancy or within 14 weeks post-partum, and 1229 controls naive for VT, 313 cases and 353 controls donated biological material. Results The odds ratios for venous thrombosis during pregnancy or puerperium were 5.0 (95% CI 3.1 to 8.3) and 9.4 (2.1-42.4) for heterozygous carriers of the factor V Leiden and the prothrombin gene polymorphisms, respectively. All homozygous carriers of the factor V Leiden (n=8) and the prothrombin polymorphism (n=1) developed VT indicating a very high risk of VT. We estimated that pregnancy-related VT occurred in 1.1/1000 non-carriers, in 5.4/1000 heterozygous carriers of factor V Leiden, and in 9.4/1000 heterozygous carriers of the prothrombin polymorphism. To avoid one VT, the number of pregnant women needed to screen for these two polymorphisms and the number needed to be given thromboprophylaxis were 2015 and 157, respectively. Conclusions Although the relative risk for VT during pregnancy and after delivery was increased among carriers of the factor V Leiden and the prothrombin polymorphisms, the overall probability for pregnancy-related VT was low. Trial registration www.clinicaltrials.gov identifier number NCT00856076.

• Tjeldhorn, Lena; Iversen, Nina; Sandvig, Kirsten; Bergan, Jonas; Sandset, Per Morten & Skretting, Grethe (2010). Functional characterization of the protein C A267T mutation: evidence for impaired secretion due to defective intracellular transport. BMC Cell Biology. ISSN 1471-2121. 11. doi: 10.1186/1471-2121-11-67. Vis sammendrag

  Background Activated protein C (PC) is a serine protease that regulates blood coagulation by inactivating coagulation factors Va and VIIIa. PC deficiency is an autosomally inherited disorder associated with a high risk of recurrent venous thrombosis. The aim of the study was to explore the mechanisms responsible for severe PC deficiency in a patient with the protein C A267T mutation by in-vitro expression studies. Results Huh7 and CHO-K1 cells were transiently transfected with expression vectors containing wild-type (WT PC) and mutated PC (A267T PC) cDNAs. PC mRNA levels were assessed by qRT-PCR and the PC protein levels were measured by ELISA. The mRNA levels of WT PC and A267T PC were similar, while the intracellular protein level of A267T PC was moderately decreased compared to WT PC. The secretion of A267T PC into the medium was severely impaired. No differences in molecular weights were observed between WT and A267T PC before and after treatment with endo-beta-N-acetylglucosaminidase. Proteasomal and lysosomal degradations were examined using lactacystin and bafilomycin, respectively, and revealed that A267T PC was slightly more susceptible for proteasomal degradation than WT PC. Intracellular co-localization analysis indicated that A267T PC was mainly located in the endoplasmic reticulum (ER), whereas WT PC was observed in both ER and Golgi. Conclusions In contrast to what has been reported for other PC mutants, intracellular degradation of A267T PC was not the main/dominant mechanism underlying the reduced intracellular and secretion levels of PC. Our results indicate that the A267T mutation most likely caused misfolding of PC, which might lead to increased retention of the mutated PC in ER.

• Enden, Tone Rønnaug; Storås, Tryggve; Negård, Anne; HAIG, YLVA; Sandvik, Leiv & Gjesdal, Kjell-Inge [Vis alle 8 forfattere av denne artikkelen] (2010). Visualization of Deep Veins and Detection of Deep Vein Thrombosis (DVT) With Balanced Turbo Field Echo (b-TFE) and Contrast-Enhanced T1 Fast Field Echo (CE-FFE) Using a Blood Pool Agent (BPA). Journal of Magnetic Resonance Imaging. ISSN 1053-1807. 31(2), s. 416–424. doi: 10.1002/jmri.22046. Vis sammendrag

  Purpose: To assess image quality, vessel visualization, preliminary diagnostic properties, and interobserver variability of a novel balanced turbo field echo (b-TFE) sequence and contrast-enhanced T1 fast field echo (CE-FFE) sequence with blood pool agent (BPA). Materials and Methods: A total of 15 healthy volunteers and six patients with ultrasound-verified proximal deep vein thrombosis (DVT) were examined from the inferior vena cava (IVC) to the proximal calf veins. Results: The great majority of deep veins were completely visualized on both sequences. In healthy volunteers the IVC was completely visualized in five b-TFE and 11 CE-FFE scans, and partially in seven b-TFE and four CE-FFE scans (P = 0.008). Poorest image quality was in the pelvis. Contrast-to-noise ratio (CNR) was higher on b-TFE compared to CE-FFE, with significant difference in calf images (P = 0.036). Sensitivity was 100% for proximal DVT with both methods. Specificity was 70% (CE-FFE) and 80% (b-TFE) for proximal femoral DVT; 100% in distal femoral. Interobserver reliability was kappa 1.0 (b-TFE), 0.9 (CE-FFE) for proximal, and overall poor for distal DVT. Conclusion: Contrast-enhancement did not add valuable information in visualizing deep veins of the lower limbs compared to b-TFE, though the IVC was slightly better visualized. Diagnostic properties and interobserver reliability of both sequences were good for proximal DVT and poor for distal DVT.

• Bergrem, Astrid; Jacobsen, Eva-Marie; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Skogstad, Marie Jeanette & Sandset, Per Morten (2010). The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis - a population-based case-control study. Thrombosis Research. ISSN 0049-3848. 125(5), s. E222–E227. doi: 10.1016/j.thromres.2009.12.006. Vis sammendrag

  In this population-based case-control study we explored the association of antiphospholipid antibodies with pregnancy-related venous thrombosis. From 1990 through 2003 615 pregnant women were identified at 18 hospitals in Norway with a diagnosis of first time VT. In 2006, 531 of 559 eligible cases and 1092 of 1229 eligible controls were invited for further investigations. The final study population comprised 313 cases and 353 controls, who completed a comprehensive questionnaire and donated a single blood sample, 3-16years after index pregnancy. We report the results on lupus anticoagulant, anticardiolipin antibodies, and anti-ss(2) glycoprotein-1 antibodies alone, in combination, and with the contribution of the factor V Leiden and the prothrombin gene G20210A polymorphisms. Cut-off values for APAs were chosen according to current international consensus. 29 (9.3%) of the cases and 24 (6.8%) of the controls had at least one positive test for APAs (OR 1.4; 95% CI 0.8-2.5). Nine cases (2.8%) and no controls had more than one positive test (multi-positivity) for APAs. After excluding women with factor V Leiden or prothrombin polymorphisms, still 6 cases were multi-positive for APAs. We conclude that multi-positivity, but not single-positivity, for APAs was weakly associated with a history of ante- and postnatal VT.

• Skretting, Grethe; Stavik, Benedicte; Landvik, Nina Elisabeth; Myklebust, Christiane Filion; Iversen, Nina & Zienolddiny , Shanbeh [Vis alle 7 forfattere av denne artikkelen] (2010). Functional characterization of polymorphisms in the human TFPI gene. Biochemical and Biophysical Research Communications - BBRC. ISSN 0006-291X. 397(1), s. 106–111. doi: 10.1016/j.bbrc.2010.05.078. Vis sammendrag

  Tissue factor pathway inhibitor (TFPI) is the primary physiological inhibitor of tissue factor (TF) induced coagulation. Low plasma TFPI levels have been shown to be associated with increased risk of arterial and venous thrombosis. Several clinical studies have reported that single nucleotide polymorphisms (SNPs) in the regulatory regions of the gene, such as the -287T/C, the -399C/T, and the -33T/C SNPs, may affect plasma TFPI levels. However, molecular studies investigating the functionality of the polymorphisms are lacking. In this study, we found that the -287C and -399T alleles affected the activity of the promoter using a reporter gene system. This was also the case for the -33T/C polymorphism. An association regarding the transcriptional activity of the reporter gene was detected between the -287C allele and the -33T/C polymorphism. Analysis of the polymorphic sites with electrophoretic mobility shift assay (EMSA) showed that all three polymorphisms potentially alter DNA protein interactions. Based on these findings, we speculate that the -287C and the -33C alleles can be associated with lowered risk of thrombosis.

• Opstad, Trine Baur; Eilertsen, Anette Løken; Høibraaten, Else; Skretting, Grethe & Sandset, Per Morten (2010). Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy. Blood Coagulation and Fibrinolysis. ISSN 0957-5235. 21(6), s. 516–521. doi: 10.1097/MBC.0b013e32833a06cd.
• Stavik, Benedicte; Skretting, Grethe; Sletten, Marit; Sandset, Per Morten & Iversen, Nina (2010). Overexpression of both TFPIα and TFPIß induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Molecular Carcinogenesis. ISSN 0899-1987. 49, s. 951–963. doi: 10.1002/mc.20679. Vis sammendrag

  Thrombosis is a major complication and an important cause of death in cancer patients. Tumor cells may trigger coagulation and induce a prothrombotic phenotype, which in return may enhance angiogenesis, tumor growth, and metastasis. Tissue factor pathway inhibitor (TFPI) has been reported to reduce tumor growth and metastasis in vivo and to induce apoptosis and inhibit proliferation in normal cells in vitro. However, no effect has so far been observed in cancer cells. We therefore aimed to characterize the functional effects of ectopic overexpression and endogenous downregulation of TFPI in cancer cells, and to elucidate possible mechanisms involved. The tumor derived breast cancer cells SK-BR-3 and Sum102 were used to construct stable cell lines overexpressing TFPIa and TFPIb, and with TFPI knocked down, respectively. Effects of altered TFPI expression were evaluated by measuring apoptosis and proliferation of the cells, and gene expressions were analyzed using PCR arrays. Increased DNA fragmentation and Caspase 3 activity was observed in SK-BR-3 cells overexpressing TFPIa and TFPIb, while a decrease in apoptosis was seen in Sum102 cells with TFPI expression knocked down. An increase and reduction in expression of pro- and antiapoptotic genes, respectively, were seen in TFPI overexpressing cells, and the majority of the upregulated genes encoded proteins involved in the death receptor pathway, among them the death receptor ligand TNF-a. In conclusion, TFPIa and TFPIb induced apoptosis in breast cancer cells and increased expression of apoptotic genes indicating a possible involvement of the death receptor pathway.

• Sandset, Per Morten; Høibraaten, Else; Eilertsen, Anette Løken & Dahm, Anders Erik A (2009). Mechanisms of thrombosis related to hormone therapy. Thrombosis Research. ISSN 0049-3848. 123, s. S70–S73. doi: 10.1016/S0049-3848(09)70015-5. Vis sammendrag

  Combined oral contraceptives and combined oral postmenopausal hormone therapy are associated with a weak, but clinically significant risk of arterial and venous thrombosis (VT). The effects are related to dose of estrogen and type of progestin. The main effects are increase in markers of activated coagulation, reduction in coagulation inhibitors, and acquired activated protein C resistance. Reduction in tissue factor pathway inhibitor (TFPI) is probably an important mechanism, which predicts activation of coagulation and acquired resistance to activated protein C. Coagulation markers should be used as intermediate or surrogate markers in early pharmacodynamic studies to evaluate the risk associated with new formulations.

• Negaard, Helene Francisca Stigter; Svennevig, Katja Christiane; Kolset, Svein Olav; Iversen, Nina; Bowitz-Lothe, IM & Østenstad, Bjørn [Vis alle 8 forfattere av denne artikkelen] (2009). Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. Leukemia and Lymphoma. ISSN 1042-8194. 50(6), s. 998–1004. doi: 10.1080/10428190902889270. Vis sammendrag

  Bone marrow angiogenesis is increased in non-Hodgkin lymphomas (NHL). Compounds affecting extracellular matrix (ECM) may modify angiogenesis. Here we investigated ECM regulators in 48 unselected NHL patients compared with 35 controls. Untreated patients had elevated (P < 0.05) serum matrix metalloproteinase (MMP) 9 and tissue inhibitor of metalloproteinase (TIMP) 1, while MMP-2, TIMP-2 and syndecan-1 were not significantly different from controls. MMP-9 mRNA was significantly up-regulated in blood mononuclear cells, while mRNA expressions of the other ECM regulators were unaltered. We found strong correlations between mRNA expressions of both vascular endothelial growth factor and fibroblast growth factor 2, and MMP-9, TIMP-1 and TIMP-2. After therapy, serum MMP-2 increased while MMP-9 decreased (P < 0.05), the others being unchanged. Several compounds affecting ECM may be involved in angiogenic activity in NHL.

• Enden, Tone Rønnaug; Kløw, Nils-Einar; Sandvik, Leiv; Slagsvold, Carl Erik; Ghanima, Waleed & Hafsahl, Geir [Vis alle 11 forfattere av denne artikkelen] (2009). Catheter-directed thrombolysis versus anticoagulant therapy alone in deep vein thrombosis: Results of an open randomized, controlled trial reporting on short term patency. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 7(8), s. 1268–1275. doi: 10.1111/j.1538-7836.2009.03464.x. Vis sammendrag

  Background: Approximately one in four patients with acute proximal deep vein thrombosis (DVT) given anticoagulation and compression therapy develop post-thrombotic syndrome (PTS). Accelerated removal of thrombus by thrombolytic agents may increase patency and prevent PTS. Objectives: To assess short-term efficacy of additional catheterdirected thrombolysis (CDT) compared with standard treatment alone. Patients and methods: Open, multicenter, randomized, controlled trial. Patients (18–75 years) with iliofemoral DVT and symptoms < 21 days were randomized to receive additional CDT or standard treatment alone. After 6 months, iliofemoral patency was investigated using duplex ultrasound and air-plethysmography assessed by an investigator blinded to previous treatment. Results: One hundred and three patients (64 men, mean age 52 years) were allocated additional CDT (n = 50) or standard treatment alone (n=53). After CDT, grade III (complete) lysis was achieved in 24 and grade II (50%–90%) lysis in 20 patients. One patient suffered major bleeding and two had clinically relevant bleeding related to the CDT procedure. After 6 months, iliofemoral patency was found in 32 (64.0%) in the CDT group vs. 19 (35.8%) controls, corresponding to an absolute risk reduction (RR) of 28.2% (95% CI: 9.7%–46.7%; P = 0.004). Venous obstruction was found in 10 (20.0%) in the CDT group vs. 26 (49.1%) controls; absoluteRR29.1%(95%CI: 20.0%–38.0%; P = 0.004). Femoral venous insufficiency did not differ between the two groups. Conclusions: After 6 months, additional CDT increased iliofemoral patency from 36% to 64%. The ongoing long-term follow-up of this study will document whether patency is related to improved functional outcome.

• Abildgaard, Ulrich; Sandset, Per Morten; Hammerstrøm, Jens; Gjestvang, Finn Tore & Tveit, Arnljot (2009). Management of pregnant women with mechanical heart valve prosthesis: Thromboprophylaxis with Low molecular weight heparin. Thrombosis Research. ISSN 0049-3848. 124(3), s. 262–267. doi: 10.1016/j.thromres.2008.12.005.
• Enden, Tone; Garratt, Andrew Malcolm; Kløw, Nils-Einar & Sandset, Per Morten (2009). Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific questionnaire. Scandinavian Journal of Caring Sciences. ISSN 0283-9318. 23(2), s. 369–374. doi: 10.1111/j.1471-6712.2008.00618.x.
• Schulman, S; Kearon, C; Kakkar, A; Mismetti, P; Schellong, S & Eriksson, H [Vis alle 10 forfattere av denne artikkelen] (2009). Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine. ISSN 0028-4793. 361(24).
• Negaard, Helene Francisca Stigter; Iversen, Nina; Bowitz-Lothe, IM; Sandset, Per Morten; Steinsvik, Brit & Østenstad, Bjørn [Vis alle 7 forfattere av denne artikkelen] (2009). Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia. ISSN 0887-6924. 23(1), s. 162–169. doi: 10.1038/leu.2008.255. Vis sammendrag

  Antiangiogenic drugs are currently tested in haematological malignancies. As these drugs target different angiogenic regulators, and as cancers are inherently heterogeneous, a detailed characterization of angiogenesis in individual cancers is needed. Hence, we measured bone marrow microvessel density (MVD), plasma concentrations of eight angiogenesis-related parameters and the expression in blood mononuclear cells of 40 angiogenesis-related mRNAs in 93 patients with haematological neoplasias (acute myeloid leukaemia; chronic lymphatic leukaemia; multiple myeloma (MM); or non-Hodgkin's lymphoma (NHL)) before start and after completion of cancer therapy. Compared with healthy individuals, the patients had significantly increased bone marrow MVD, especially patients with advanced stage disease. A novel finding was that patients with NHL also had increased bone marrow MVD. The plasma levels of vascular endothelial growth factor (VEGF), interleukin (IL)-6 and IL-8 were significantly increased. VEGF levels were highest in those who did not achieve complete remission after cancer therapy. The mRNA expression of IL-8 was upregulated 15-fold. Our data show that patients with haematological malignancies have increased bone marrow MVD; hence, supporting the notion that bone marrow angiogenesis plays a role in the pathogenesis and progression of these cancers. VEGF, IL-6 and IL-8 seem to contribute to the malignant phenotype.

• Skretting, Grethe; Lien, Trude; Sandset, Per Morten & Iversen, Nina (2009). Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability. Thrombosis Research. ISSN 0049-3848. 123(6), s. 851–855. doi: 10.1016/j.thromres.2008.09.003. Vis sammendrag

  Introduction: Tissue factor (TF) pathway inhibitor (TFPI) is the endogenous inhibitor regulating TF-induced blood coagulation. Several polymorphisms have been identified in the TFPI gene and some of them correlated with variations in plasma TFPI levels. The aim of the present study was to characterize the TFPIV264M mutant in comparison with the wild type protein (TFPIWT). Materials and methods: We have overexpressed the TFPIV264M mutant and TFPIWT in human coronary artery endothelial cells and compared the expression and activity levels of the mutated protein relative to the TFPIWT. The protein levels were determined by ELISA, the inhibitory activity of the proteins was assessed with a chromogenic substrate assay. The mRNA level of the two TFPI variants was determined using real time RT-PCR. MFOLD was used to predict mRNA secondary structure. Results and conclusions: TFPIV264M displayed increased protein levels and activity compared to TFPIWT accompanied by an increase in mRNA levels of TFPIV264M due to prolonged stability of TFPIV264M mRNA. The specific activity of the TFPIV264M was similar to TFPIWT, indicating that the mutation does not affect the enzymatic function of the protein.

• Skretting, Grethe; Stavik, Benedicte; Myklebust, Christiane Filion; Sandset, Per Morten & Iversen, Nina (2009). Functional studies of the 5¢UTR and intron 7 SNPs of the TFPI gene. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 7.
• Stavik, Benedicte; Skretting, Grethe; Sletten, Marit; Frengen, Eirik; Sandset, Per Morten & Iversen, Nina (2009). Knockdown of TFPI expression in Sum102 breast cancer cells leads to pro-angiogenic phenotypes. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 7.
• Hofstad, Bjørn; Nesbakken, Arild; Eritsland, Jan; Brørs, Odd & Sandset, Per Morten (2008). Should platelet inhibitors be discontinued before gastrointestinal endoscopy?]. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 128(21), s. 1440–2442.
• Jacobsen, Anne Flem; Skjeldestad, Finn Egil & Sandset, Per Morten (2008). Incidence and Risk Patterns of Venous Thromboembolism In Pregnancy and Puerperium – A Register-Based Case-Control Study. American Journal of Obstetrics and Gynecology. ISSN 0002-9378. 198(2), s. 233.e1–233.e7. doi: 10.1016/j.ajog.2007.08.041. Vis sammendrag

  Objective: To estimate the incidence of venous thromboembolism (VTE) in pregnancy and puerperium and to identify risk factors for pregnancy-related VTE. Study Design: A register-based case-control study with 613232 pregnancies from 1990 to 2003 in eleven Norwegian counties. Medical records for eligible cases were revisited and relevant medical data were transferred to a specific case-report-form. The diagnosis of VTE was based on strict criteria. Data were analyzed by chi-square test and forward stepwise logistic regression. Results: In total 615 cases were detected. The incidence of VTE was 1/1000 pregnancies. The ante- and postnatal incidences were quite similar. Antenatal risk factors were assisted reproduction, gestational diabetes, age over 35 years, multiple pregnancies, and primi-parity. Postnatal risk factors were Cesarean section, preeclampsia, assisted reproduction, abruptio placenta, and placenta previa. Conclusion: We found different ante- and postnatal risk patterns. Assisted reproduction and gestational diabetes were significant antenatal risk factors while Cesarean section and preeclampsia were strong postnatal risk factors.

• van Vliet, Huib AAM; Bertina, Rogier M; Dahm, Anders Erik A; Rosendaal, Frits; Rosing, Jan & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2008). Different effects of oral contraceptives containing different progestogens on protein S and Tissue Factor Pathway Inhibitor. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 6(2), s. 346–351. doi: 10.1111/j.1538-7836.2007.02863.x. Vis sammendrag

  Background. Oral contraceptives (OC) containing different types of progestogens induce different sensitivities to activated protein C (APC) measured with the thrombin generation-based APC-resistance test. These differences in APC resistance may be the biological explanation for the differences in thrombotic risk of the various pills. The mechanistic basis of APC resistance observed in OC users is unknown. Our objective was to study the effect of OC on the two main determinants of the APC-resistance test, free protein S and free tissue factor pathway inhibitor (TFPI). Patients/Methods. We measured free protein S and free TFPI in 156 users of various types of OC. Results. Users of desogestrel-containing OC, known to double the risk of thrombosis compared to levonorgestrel-containing OC, had lower free protein S (24 versus 33 U/dL) and TFPI free antigen (2.9 versus 3.6 ng/mL) levels than users of OC containing levonorgestrel. Women using cyproterone acetate-containing OC, known to confer a high thrombotic risk, had the lowest free protein S (19 U/dL) and free TPFI antigen (2.5 ng/mL) levels. Users of OC containing drospirenone had lower free protein S (23 U/dL) and TFPI antigen levels (3.2 ng/mL) than users of levonorgestrelcontaining OC. Low free protein S and low free TFPI antigen levels were associated with an increased resistance to APC, an established risk factor for thrombosis. Conclusions. This study observed that the differences in APC resistance induced by OC containing different progestogens can at least in part be explained by different effects of OC on free protein S and TFPI.

• Eilertsen, Anette Løken; Karssemeijer, Nico; Skaane, Per; Qvigstad, Erik & Sandset, Per Morten (2008). Differential Impact of Conventional and Low Dose Oral Hormone Therapy, Tibolone and Raloxifene on Mammographic Breast Density, Assessed by an Automated Quantitative Method. British Journal of Obstetrics and Gynaecology. ISSN 0306-5456. 115(6), s. 773–779. doi: 10.1111/j.1471-0528.2008.01690.x.. Vis sammendrag

  Objective To evaluate impact of different postmenopausal hormone therapy (HT) regimens and raloxifene on mammographic breast density. Design Open, randomised, comparative clinical trial. Setting Women were recruited through local newspapers and posters. They were examined at the departments of haematology, gynaecology, and radiology in a University Hospital. Population 202 healthy postmenopausal women, between the age of 45 and 65 years. Methods Subjects were randomly assigned to receive daily treatment for 12 weeks with tablets containing either low-dose HT containing 1 mg 17 -estradiol + 0.5 mg norethisterone acetate (NETA)(n=50), conventional-dose HT containing 2 mg 17 -estradiol and 1 mg NETA (n=50), 2.5 mg tibolone (n=51), or 60 mg raloxifene (n=51). Mammographic density was determined at baseline and after 12 weeks by an automated technique in full-field digital mammograms (FFDM). Main outcome measures Mammographic density was expressed as Volumetric Breast Density Estimations. Results Mammographic breast density increased significantly and to a similar degree in both the conventional- and low-dose HT group. A small reduction in mammographic breast density was seen in the raloxifene group, whereas those allocated to tibolone treatment only showed minor changes. Conclusions Our findings demonstrated a significant difference in impact on mammographic breast density between the regimens. Although these results indicate a differential effect of these regimens on breast tissue the relation to breast cancer risk remains unresolved.

• Jacobsen, Anne Flem; Skjeldestad, Finn Egil & Sandset, Per Morten (2008). Ante-and postnatal risk factors of venous thrombosis – a hospital-based case-control study. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 6, s. 905–912. doi: 10.1111/j.1538-7836.2008.02961.x. Vis sammendrag

  Objective: To study ante- and postnatal risk factors of venous thrombosis (VT) in pregnancy. Methods: A hospital-based case-control study. Cases were women with objectively verified VT during pregnancy or postpartum. Two controls were selected for each case. Validated risk factors were analyzed by chi-square test and logistic regression. Results: In total 559 cases with no prior VT, 268 ante- and 291 postnatal cases, were identified together with 1229 controls. Risk factor for antenatal VT were assisted reproduction technique (ART), antepartum immobilization, cigarette smoking, and slight weight gain (<7 kg). Conception after ART and multiple pregnancy showed additive effect, whereas antepartum immobilization and high body mass index (BMI) showed multiplicative effect on the risk for antepartum VT. No other interaction was found between risk factors for antepartum VT. Risk factors for postnatal VT were antepartum immobilization, cigarette smoking, IUGR, preeclampsia, emergency caesarean section, postpartum hemorrhage, infection, and surgery, and age and parity. Antepartum immobilization and high BMI and reoperation on the indication bleeding showed multiplicative effects on the risk of postnatal VT. Conclusions: Ante- and postpartum risk factors differed markedly. More attention should be paid to pregnant women of high BMI who are at risk for immobilization.

• Eilertsen, Anette Løken; Sandvik, Leiv; Steinsvik, Brit & Sandset, Per Morten (2008). Differential Impact of Conventional Dose and Low Dose Postmenopausal Hormone Therapy, Tibolone and Raloxifene on C-Reactive Protein and other Inflammatory Markers. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 6, s. 928–934. doi: 10.1111/j.1538-7836.2008.02970.x. Vis sammendrag

  Background Postmenopausal hormone therapy (HT) is associated with an increased risk for arterial and venous thrombosis. Objectives To compare the impact of HT, tibolone, and raloxifene on C-reactive protein (CRP) and other inflammatory markers, and to investigate possible underlying mechanisms for changes in CRP and D-dimer. Methods 202 healthy women were randomly assigned to treatment for 12 weeks with either low-dose HT containing 1 mg 17 -estradiol + 0.5 mg norethisterone acetate (NETA)(n=50), conventional-dose HT containing 2 mg 17 -estradiol and 1 mg NETA (n=50), 2.5 mg tibolone (n=51), or 60 mg raloxifene (n=51). Results CRP increased in the conventional and low-dose HT-group. These changes were significantly more pronounced in the conventional-dose group (RMANOVA p=0.02). Also tibolone was associated with an increase in CRP, in contrast to raloxifene which reduced CRP. Reduction in levels of Lp (a), ICAM, P-selectin, E-selectin, MCP-1 and IL-6 were observed in all treatment groups. The changes were most pronounced for the conventional dose HT group, least pronounced for the raloxifene, whereas the changes in those allocated to tibolone and low-dose HT were intermediary. Increased levels of TNF- and vWf ag were seen in the raloxifene group. We observed positive associations between changes in IL-6, vWf ag, MCP-1 and CRP. Conclusions The regimens had markedly different impact on markers of inflammation. The average increase in CRP was not accompanied by an increase in average IL-6 or TNF- or other markers, but women with large reductions in IL-6 had reduced increase in CRP.

• Negaard, Helene Francisca Stigter; Iversen, Per Ole; Østenstad, Bjørn; Iversen, Nina; Holme, Pål Andre & Sandset, Per Morten (2008). Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. Thrombosis and Haemostasis. ISSN 0340-6245. 99, s. 1040–1048. doi: 10.1160/TH07-09-0541. Vis sammendrag

  Patients with haematological malignancies carry increased risk of venous thrombosis (VT). However, the mechanisms that link these malignancies to activated coagulation have not been fully identified. Since anti-haemostatic agents are studied in clinical trials for their potential to prolong survival in cancer patients, a detailed characterisation of haemostatic markers in cancer subtypes is needed. Hence, in this study, we measured the plasma concentrations and mRNA expression in blood mononuclear cells of haemostatic parameters in 93 patients with haematological neoplasias (acute myeloid leukaemia, chronic lymphatic leukaemia, multiple myeloma, and non-Hodgkin’s lymphoma) before start and after completion of cancer therapy. At diagnosis we found activation of coagulation and fibrinolysis, especially in patients with acute myeloid leukaemia. This hypercoagulation was not associated with increased levels of tissue factor (TF) or factor VII (fVII) antigen or mRNA, or levels of activated fVII. In conclusion we found a hypercoagulable state in patients with haematological malignancy that did not seem to be initiated by TF.

• Negaard, Helene Francisca Stigter; Iversen, Per Ole; Østenstad, Bjørn; Mowinckel, Marie-Christine & Sandset, Per Morten (2008). Increased acquired activated protein C resistance in unselected patients with hematological malignancies. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 6, s. 1482–87. doi: 10.1111/j.1538-7836.2008.03060.x. Vis sammendrag

  Background: We have previously found that activation of coagulation in patients with various hematological malignancies was apparently not initiated by tissue factor (TF). Acquired activated protein C (APC) resistance may be another mechanism responsible for such hypercoagulation, and has been demonstrated in patients with solid tumors, but not in patients with hematological malignancy. Objective: To investigate acquired APC resistance in a hypercoagulable cohort of patients with hematological malignancies. Patients/methods: Blood samples from 93 patients with acute myeloid leukemia (AML), chronic lymphatic leukemia, multiple myeloma, or non-Hodgkin's lymphoma, were analyzed before start and after completion of cancer therapy. APC resistance was measured using calibrated automated thrombography. The APC sensitivity ratio (APC-SR) was calculated as the ratio of the endogenous thrombin potential (ETP) determined in plasma probed with either APC or buffer. Results: Untreated patients were found to have higher APC-SR than healthy controls, and AML patients had higher APC-SR as compared to the other diagnoses, both findings being consistent with acquired APC resistance. The acquired APC resistance was partly ameliorated with cancer treatment. Decreased levels of protein S and tissue factor pathway inhibitor were inversely correlated to APC resistance. Conclusions: APC resistance may contribute to the hypercoagulable state in hematological malignancies.

• Jacobsen, Anne Flem; Skjeldestad, Finn Egil & Sandset, Per Morten (2008). Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 6(6), s. 905–912. doi: 10.1111/j.1538-7836.2008.02961.x.
• Sandset, Per Morten & Wisløff, Finn Georg B (2007). Blodsykdommer. I Vilberg, Astri (Red.), Norsk legemiddelhåndbok for helsepersonell 2007. Foreningen for utgivelse av Norsk Legemiddelhåndbok. ISSN 978-82-90732-09-2. s. 147–172.
• Sandset, Per Morten & Wisløff, Finn Georg B (2007). Legemidler ved blodsykdommer. I Vilberg, Astri (Red.), Norsk legemiddelhåndbok for helsepersonell 2007. Foreningen for utgivelse av Norsk Legemiddelhåndbok. ISSN 978-82-90732-09-2. s. 815–848.
• Sandset, Per Morten (2007). Hematologi. I Bendz, Bjørn & Aabakken, Lars (Red.), Turnuslegeboka. Legeforlaget. ISSN 978-82-99-35687-9. s. 154–166.
• Sandset, Per Morten & Wisløff, Finn Georg B (2007). Legemidler og bruken av dem. I Nordeng, Hedvig M Egeland & Spigset, Olav (Red.), Legemidler og bruken av dem. Gyldendal Akademisk. ISSN 978-82-05-32365-0. s. 197–204.
• Ghanima, Waleed Khalid; Abdelnoor, Michael; Holmen, Lars Olaf; Nielssen, BE & Sandset, Per Morten (2007). The association between the proximal extension of the clot and the severity of pulmonary embolism (PE): a proposal for a new radiological score for PE. Journal of Internal Medicine. ISSN 0954-6820. 261, s. 74–81. doi: 10.1111/j.1365-2796.2006.01733.x. Vis sammendrag

  The aim of the study was to investigate the association between the proximal level of the clot and the severity of pulmonary embolism (PE). The cohort consisted of 99 consecutive patients with PE diagnosed by multi-detector CT. A new score was constructed by calculating the mean value of the largest affected vessel (sub-segmental=1, segmental=2, lobar=3, main pulmonary artery (MPA)=4) in each lung. A significant association was found between the most proximal level of PE and pulmonary artery obstruction index (PAOI) (p<0.0001), right ventricular (RV)/left ventricular (LV) ratio (p<0.0001), and PaO2 (p=0.004). No significant association was found between systolic blood pressure and the level of PE. Troponin-T was elevated in none of the sub-segmental, 5% of segmental, 20% of lobar, and in 56% of PEs in the MPA (p=0.001). Significant association was found between the proposed score and PAOI (p<0.0001), RV/LV ratio (p<0.0001), PaO2 (p<0.008). Troponin-T was elevated in 10% of level 1, 0% of level 2, 43% level of 3, 66% of level 4 PE (p<0.0001). Cut-off level score 4 yielded a sensitivity of 84% and a specificity of 74% for the detection of elevated Troponin-T. In conclusion the study indicates that both the most proximal level of PE and the proposed score are related to the severity of PE as determined by blood oxygenation, biochemical and radiological parameters and could therefore be of value for rapid risk stratification of PE. However, the prognostic value of these classifications and their clinical significance needs to be evaluated in properly designed studies.

• Eilertsen, Anette Løken; Sandvik, Leiv; Mowinckel, M.C.; Andersen, Trine Opstad; Qvigstad, Erik & Sandset, Per Morten (2007). Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thrombosis Research. ISSN 0049-3848. 120, s. 371–379. doi: 10.1016/j.thromres.2006.10.013. Vis sammendrag

  Introduction. We have recently reported that different hormone regimens given to healthy post-menopausal women had markedly different effects on activation of coagulation. Low-dose hormone therapy (HT) and raloxifene, as opposed to conventional-dose HT and tibolone, were associated with no or minor activation of coagulation. The aim of this study was to elucidate the mechanism(s) for differences in coagulation activation by analysing clotting and fibrinolytic factors and coagulation inhibitors. Materials and Methods. 202 healthy women were randomly assigned to receive treatment for 12 weeks with either low dose HT containing 1 mg 17 -estradiol + 0.5 mg norethisterone acetate (NETA) (n=50), conventional dose HT containing 2 mg 17 -estradiol and 1 mg NETA (n=50), 2.5 mg tibolone (n=51), or 60 mg raloxifene (n=51) in an open-label design. Results. The conventional- and low-dose HT groups generally showed similar effects, i.e., reductions in both clotting factors and inhibitors, but the effects were markedly more pronounced in the conventional-dose HT group. Compared with the low-dose HT group those treated with tibolone showed more pronounced decreases in factor VII, less reduction of antithrombin and protein C and even increased levels in protein S and tissue factor pathway inhibitor. As opposed to the low-dose HT group the reductions in inhibitors in the raloxifene group were smaller. Moreover in those allocated to raloxifene reduced levels of fibrinogen were seen. Conclusions. Our study demonstrates that the different HT regimens and raloxifene exert differential effects on coagulation factors, inhibitors and fibrinolytic factors.

• Berge, Eivind; Foss, Kari Bente; Sandset, Else Charlotte; Haugbro, Kaia Kristine; Turkovic, Meliha & Sandset, Per Morten (2007). The Factor V Leiden, Prothrombin Gene 20210GA, Methylenetetrahydrofolate Reductase 677CT and Platelet Glycoprotein IIIa 1565TC Mutations in Patients With Acute Ischemic Stroke and Atrial Fibrillation. Stroke. ISSN 0039-2499. 38, s. 1069–1071. doi: 10.1161/01.STR.0000258076.04860.8e. Vis sammendrag

  BACKGROUND AND PURPOSE: We wanted to investigate whether common prothrombotic mutations are more prevalent in patients with atrial fibrillation who have had a stroke than in healthy controls. We also wanted to assess whether early recurrent ischemic cerebrovascular events were more frequent among carriers of the factor V Leiden or the prothrombin gene mutations than among others. METHODS: We used a case-control design with 367 patients with acute ischemic stroke and atrial fibrillation (cases) and 482 healthy blood donors (controls). All mutations were detected with conventional polymerase-chain reaction protocols. RESULTS: The odds ratios for carriers of the factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT, or platelet glycoprotein IIIa 1565TC (Pl(A2)) mutation were 0.91, (95% CI, 0.51 to 1.59), 2.25 (95% CI, 0.61 to 8.90), 0.83 (0.61 to 1.13), and 0.79 (0.57 to 1.10), respectively. Early recurrent ischemic stroke and total recurrent ischemic cerebrovascular events were slightly more frequent among carriers of the factor V Leiden mutation than among noncarriers: odds ratio 1.45 (95% CI, 0.41 to 5.1), and 1.59 (0.61 to 4.1), respectively. None of the patients with recurrent ischemic cerebrovascular events had the prothrombin gene mutation. CONCLUSIONS: These mutations are not important risk factors for thromboembolic stroke associated with atrial fibrillation. Carriers of the factor V Leiden mutation had a small, nonsignificantly higher risk of early recurrent ischemic cerebrovascular events.

• Andresen, Marianne Seierstad; Eilertsen, Anette Løken; Abildgaard, Ulrich & Sandset, Per Morten (2007). Hormone therapy and raloxifene reduce the coagulation inhibitor potential. Blood Coagulation and Fibrinolysis. ISSN 0957-5235. 18, s. 455–460. Vis sammendrag

  Background The Coagulation Inhibitor Potential (CIP) assay is a global assay that may detect major thrombophilia at a sensitivity of 100% and a specificity of 70-80%. Subnormal CIP may be associated with increased risk of venous thromboembolism (VTE). Aims Compare the effect on CIP in plasma samples from postmenopausal women treated with four different therapeutic regimens. Methods Fibrin aggregation in plasma was monitored after activation of coagulation with tissue factor, and the effect of potentiated inhibition of coagulation was measured. The assay was performed on plasma samples from 202 healthy women who were randomly assigned to receive treatment for twelve weeks with conventional-dose hormone therapy (HT), low-dose HT, raloxifene or tibolone. Major thrombophilias were excluded. Twelve women were heterozygous carriers of the factor V Leiden mutation. Results Compared to baseline the median level in CIP was reduced by 64% in the conventional-dose HT group, by 38% in the low-dose HT group, 31% in the raloxifene group, whereas for those treated with tibolone median CIP increased by 9%. The median changes in CIP were significant for both the HT groups (P  0.0001) and for those allocated to raloxifene (P = 0.003), but not for the tibolone group (P = 0.653). Women with heterozygous factor V Leiden mutation had significantly reduced median CIP level (P  0.0001) at baseline. Conclusions: HT and raloxifene, associated with VTE, reduce CIP. Tibolone does not reduce CIP.

• Jensen, Torstein; Kierulf, Peter; Sandset, Per Morten; Klingenberg, Olav; Joø, Gun Brit & Godal, Hans Chr [Vis alle 7 forfattere av denne artikkelen] (2007). Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from peripheral blood mononuclear cells. Thrombosis and Haemostasis. ISSN 0340-6245. 97(5), s. 822–829. doi: 10.1160/TH07-01-0039. Vis sammendrag

  Fibrinogen in plasma includes three main fractions; high-molecular-weight (HMW)-fibrinogen, low-molecular-weight (LMW)-fibrinogen, and very-low-molecular-weight (LMW')-fibrinogen. During acute-phase conditions, plasma fibrinogen levels and the HMW-/LMW-fibrinogen ratio increase rapidly due to increased synthesis of HMW-fibrinogen. The consequences of elevated plasma fibrinogen levels and local deposition of fibrin in inflammatory tissues observed during acute-phase conditions are not clear. We wanted to investigate proinflammatory effects of fibrinogen and fibrin on peripheral blood mononuclear cells (PBMC) as reflected by altered mRNA expression and synthesis of the proinflammatory cytokines IL-6, TNF-alpha and IL-1beta, and to explore the significance of altered HMW-/LMW-fibrinogen ratio. PBMC were isolated from whole blood using Lymphoprep((R)). HMW-fibrinogen was separated from unfractioned fibrinogen by ammonium sulphate precipitation. Cells were incubated with unfractioned fibrinogen, HMW-fibrinogen or fibrin. Cytokine levels in cell lysates were determined using ELISA assays. Real-time PCR was used for mRNA quantification. We found that fibrinogen significantly increased mRNA levels, and induced synthesis of the proinflammatory cytokines IL-6 and TNF-alpha in PBMC in a dose dependent manner. Median (25, 75 percentile) IL-6 and TNF-alpha concentrations were 12 (5, 40) pg/ml and 16 (0,61) pg/ml, respectively. Median mRNA quantity was increased 12.3- (6.6, 48.6) and 1.7- (1.5, 6.5) fold for IL-6 and TNF-alpha compared to controls. The stimulatory effect of unfractioned fibrinogen was not significantly different from HMW-fibrinogen. Fibrinogen and fibrin were equally effective in promoting cytokine synthesis from PBMC. The results support that fibrin and fibrinogen may actively modulate the inflammatory process by inducing synthesis of proinflammatory cytokines from PBMC.

• Ghanima, Waleed; Nielssen, BE; Holmen, Lars Olaf; Witwit, A; Al-Ashtari, A & Sandset, Per Morten (2007). Multi-detector computerized tomography (MDCT) in the diagnosis of pulmonary embolism: Inter-observer agreement among radiologists with varied levels of experience. Acta Radiologica. ISSN 0284-1851. 48(2), s. 165–170. doi: 10.1080/02841850601100859. Vis sammendrag

  Purpose: To assess the interobserver variability of radiologists with varied levels of experience in the interpretation of multidetector computed tomography (MDCT) pulmonary angiographies. Material and Methods: Review of CT pulmonary angiographies performed on patients included in a diagnostic study evaluating a decision-based algorithm for diagnosing pulmonary embolism (PE). Five radiologists, three board-certified general radiologists and two radiology trainees with 2 years’ experience, participated in the study. Results: According to the consensus reading, PE was present in 91 (31%) and absent in 194 (67%) patients, while in five patients (1.7%) the interpretations were regarded as equivocal. The per-patient agreement on the diagnosis of PE achieved by each of the four readers compared to the consensus reading was very good (k range 0.85–0.92), but peripheral emboli were missed in four to six patients by three of four observers. The agreement on the most proximal level of PE (per-proximal level) assessed by mean k value was 0.83 (k range 0.68–0.91) for the detection of proximal emboli, 0.61 for segmental emboli (k range 0.40–0.80), and 0.38 for emboli in the subsegmental vessels (k range 0.0–0.89). Conclusion: The overall agreement on the diagnosis of PE by MDCT for general radiologists and radiology trainees is very good, and we therefore believe that the initial management of patients with suspected PE could be based on the preliminary assessment performed by on-call radiologists with 2 years of experience. Key words: Alternative diagnosis; interobserver agreement; multidetector CT; pulmonary embolism

• Eilertsen, Anette Løken; Liestøl, Sigurd; Mowinckel, M.C.; Hemker, HC & Sandset, Per Morten (2007). Differential impact of conventional and low dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thrombosis and Haemostasis. ISSN 0340-6245. 97(6), s. 938–943. Vis sammendrag

  Recent studies have shown that Hormone Therapy (HT) is associated with an acquired resistance to activated protein C (APC). The aims of the present study were to evaluate a possible dose-response relationship and differential effects of different HT regimens on functionality of the APC system. 202 healthy women were randomly assigned to receive once daily treatment for 12 weeks with tablets containing either low-dose HT containing 1 mg 17 -oestradiol + 0.5 mg norethisterone acetate (NETA) (n=50), conventional-dose HT containing 2 mg 17 -oestradiol and 1 mg NETA (n=50), 2.5 mg tibolone (n=51), or 60 mg raloxifene (n=51). Normalized APC system sensitivity ratios (nAPCsr) were determined in plasma collected at baseline and after 12 weeks using a thrombin generation-based APC resistance test probed with either recombinant APC (rAPC) or by thrombomodulin (rTM). NAPCsr increased in both the conventional- and low-dose HT groups, consistent with reduced sensitivity to APC. The increase was slightly more pronounced in the conventional-dose group, but the difference between the two HT groups was not statistically significant. The sensitivity to APC was only marginally altered in those allocated to tibolone. Consequently, tibolone showed a different phenotype as compared with the low-dose HT group. A small increase in nAPCsr with both rAPC and rTM was seen in the raloxifene-group, but the increase was less than in the low-dose HT group. Conclusions Our findings indicate that oestrogen-progestin therapy induces an APC resistant phenotype, which may be related to dose, whereas tibolone and raloxifene only marginally alter the sensitivity to APC.

• Liestøl, Sigurd; Sandset, Per Morten; Mowinckel, M.C. & Wisløff, Finn Georg B (2007). Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 5(11), s. 2204–2211. Vis sammendrag

  Background: Several studies suggest that antiphospholipid antibodies interfere with the activity of activated protein C (APC). This acquired form of APC resistance has been proposed as a possible pathogenic mechanism underlying hypercoagulability associated with the antiphospholipid syndrome (APS).Objectives: We wanted to investigate the inhibitory effect of recombinant APC (rAPC) on ex vivo thrombin generation in plasma and the modification of this effect by the presence of lupus anticoagulants (LA).Patients/Methods: We analyzed plasmas from 81 patients with LA (52 patients fulfilling the criteria for the APS) and 91 controls. Percent inhibition of the endogenous thrombin potential (ETP) as a parameter of APC sensitivity was determined in plasmas using a thrombin generation-based APC resistance test probed with rAPC. All results were normalized using pooled normal plasma (PNP) as a reference.Results: Normalized percent inhibition of ETP by APC was lower in patients with LA [61.4%, 95% confidence interval (CI) 45.8-74.5%] compared to controls (107.8%, 95% CI: 107.1-109.3%). In patients with LA and APS, median inhibition was lower than in patients with LA without APS (44.6%, 95% CI: 30.1-55.7% vs. 78.8%, 95% CI: 73.9-95.8%). This difference also persisted when patients on warfarin therapy were excluded from the APS subgroup.Conclusions: APC resistance can be demonstrated with a thrombin generation-based test in a majority of patients with the LA laboratory phenotype. A history of thrombotic events in patients with LA is associated with a stronger resistance to the anticoagulant effect of APC.

• Enden, Tone; Sandvik, Leiv; Kløw, Nils-Einar; Hafsahl, Geir; Holme, Pål Andre & Holmen, Lars Olaf [Vis alle 11 forfattere av denne artikkelen] (2007). Catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis (CaVenT) study: Rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). American Heart Journal. ISSN 0002-8703. 154, s. 808–814. doi: 10.1016/j.ahj.2007.07.010. Vis sammendrag

  Background. The conventional treatment of acute deep vein thrombosis (DVT) is anticoagulation and compression therapy, as recommended in the international guidelines. Anticoagulation prevents recurrent venous thrombosis, pulmonary embolism, and death. Compression therapy reduces the risk of developing long-term sequelae, that is, postthrombotic syndrome (PTS). Evaluation of systemic thrombolysis has shown effective thrombolysis and a likely reduction in PTS but at the cost of increased risk of bleeding complications. Catheter-directed thrombolysis (CDT) was introduced for rapid removal of thrombi and salvage of venous valves with less systemic thrombolytic effect, and is being offered to selected patients with iliofemoral DVT to prevent development of PTS. Case series have shown technical and thrombolytic success; however, no randomized studies have evaluated the long-term clinical effects of venous CDT. The aim of the CaVenT study is to investigate the role of adjunctive CDT by evaluating its clinical efficacy and safety compared with conventional treatment alone in patients with acute iliofemoral DVT. Methods. The CaVenT study is an open, randomized, controlled, clinical trial. We plan to include 200 patients who will receive either CDT, in addition to conventional treatment, or conventional treatment alone. The primary outcome measures are patency at 6 months and prevalence of PTS at 2 years. Conclusion. Implementation of the CaVenT study will be a contribution toward evidence-based medicine in the treatment of acute proximal DVT of the leg. Any documentation of improved functional outcome will have a significant impact on clinical practice for this patient group and may lead to a modification of existing international guidelines.

• Tchaikovski, Svetlana N; van Vliet, Huib AAM; Thomassen, MCLGD; Bertina, Rogier M; Rosendaal, Frits & Sandset, Per Morten [Vis alle 8 forfattere av denne artikkelen] (2007). Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography (CAT). Thrombosis and Haemostasis. ISSN 0340-6245. 98, s. 1350–1356. doi: 10.1160/TH07-07-0439. Vis sammendrag

  In a study population consisting of healthy men (n=8), women not using oral contraceptives (OC) (n=28) and women using different kinds of OC (n=187) we used calibrated automated thrombography (CAT) in the absence and presence of added activated protein C (APC) to compare parameters that can be obtained from thrombin generation curves, i.e. lag time, time to peak, peak height and endogenous thrombin potential (ETP). Both with and without APC, plasmas of OC users exhibited the shortest lag time and time to peak, and the highest peak height and ETP. In the absence of APC none of these parameters differed between users of OC containing different progestogens. In contrast, in the presence of APC shorter lag times and time to peak, and higher peak height and ETP were observed in plasma of users of gestodene-, desogestrel-,drospirenone- and cyproterone acetate-containing OC than in plasma of users of levonorgestrel- containing OC. The ETP determined in the absence of APC (ETP-APC) had no predictive value for the APCsr (r=0.11; slope 0.9×10–3; 95%CI: –0.1×10–3 to 2.0×10–3) whereas the ETP measured in the presence of APC (ETP+APC) showed an excellent correlation with the APCsr (r=0.95; slope 6.6×10–3; 95%CI: 6.3×10–3 to 6.9×10–3) indicating that the APCsr is entirely determined by the ETP+APC. In conclusion, OC use increases thrombin generation, but differential effects of second and third generation OCs on the protein C system likely determine the differences in the risk of venous thrombosis between these kinds of OC.

• Ghanima, Waleed Khalid & Sandset, Per Morten (2007). Validation of a new D-dimer microparticle enzyme immunoassay (AxSYM D-Dimer) in patients with suspected pulmonary embolism (PE). Thrombosis Research. ISSN 0049-3848. 120, s. 471–476. doi: 10.1016/j.thromres.2006.11.005.
• Liestøl, Sigurd; Sandset, Per Morten; Jacobsen, Eva Marie; Mowinckel, Marie-Christine & Wisløff, Finn Georg B (2007). Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. British Journal of Haematology. ISSN 0007-1048. 136, s. 131–137. Vis sammendrag

  Inhibition of tissue factor pathway inhibitor type 1 (TFPI) is one of the mechanisms by which lupus anticoagulants (LA) may upregulate tissue factor (TF) activity. We wanted to examine whether purified immunoglobulin G (IgG) from patients with LA may interfere with the ability of TFPI to inhibit ex vivo TF-induced thrombin generation. The endogenous thrombin potential (ETP) in pooled normal plasma (PNP) supplemented with IgG from either patients with LA or controls was determined in the absence or presence of recombinant TFPI (rTFPI). In the presence of a heparin neutraliser, the ETP was also determined in plasmas from patients with LA and controls before and after heparin injection in order to quantify the anticoagulant effect of heparin-releasable TFPI in vivo. Compared with IgG from controls (n = 14), IgG from patients with LA (n = 28) induced a wide range of enhancing or inhibitory effects on the ETP in PNP. The response to rTFPI in PNP with IgG from patients with LA correlated inversely with thrombin generation (rs = 0·637, P = 0·0003). Correspondingly, the relative inhibition of ETP in postheparin plasmas was smaller for patients (n = 11) than for controls (n = 9) (32% vs. 68%, P = 0·007). Our findings support the hypothesis that TFPI anticoagulant activity is inhibited in some patients with LA.

Se alle arbeider i Cristin

• Barrabes, Veronika; Fredriksen, Magne Wang; Ronæs, Johan; Getz, Linn Okkenhaug; Sandset, Per Morten & Tangen, Marte Kvittum (2023). Fremtidens helsetjenester - kollaps eller suksess? Kommunal rapport. ISSN 0801-6410.
• Chollet Dugarte, Maria Eugenia; Andersen, Elisabeth; Harrison, Sean Philip; de la Morena-Barrio, Maria Eugenia; Baumgarten, Saphira Felicitas & Bhattacharya, Anindita [Vis alle 14 forfattere av denne artikkelen] (2023). OC 07.5 Modeling and Correcting FVII Deficiency using Human Stem Cell-Derived Hepatic Organoids. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 7(Oral communications ISTH 2023). doi: 10.1016/j.rpth.2023.100470.
• Roman, Giacomo; Lauritzen, Knut Husø; Harrison, Sean Philip; Sullivan, Gareth John; Iversen, Nina & Henriksson, Carola Elisabeth [Vis alle 10 forfattere av denne artikkelen] (2023). OC 07.1 Autologous CRISPR/Cas9 Correction of a Missense Variant from a Patient with Severe, Inherited FVII Deficiency. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 7(Oral communications ISTH 2023). doi: 10.1016/j.rpth.2023.100475.
• Lauritzen, Knut Husø; Sullivan, Gareth John; Harrison, Sean Philip; Iversen, Nina; Henriksson, Carola Elisabeth & Glosli, Heidi [Vis alle 9 forfattere av denne artikkelen] (2023). OC 07.1 Autologous CRISPR/Cas9 Correction of a Missense Variant from a Patient with Severe, Inherited FVII Deficiency. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. doi: 10.1016/j.rpth.2023.100475.
• Larsen, Trine-Lise; Ghanima, Waleed; Sandset, Per Morten; Frøen, Hege; Jacobsen, Eva-Marie & Torfoss, Dag [Vis alle 7 forfattere av denne artikkelen] (2023). Faktor Xa-hemmere til forebygging og behandling av venøs tromboembolisme ved kreft. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(1). doi: 10.4045/tidsskr.22.0228. Fulltekst i vitenarkiv
• Cui, Xueyan; Myklebust, June Helen; Munthe, Ludvig A; Schjesvold, Fredrik Hellem; Tjønnfjord, Geir Erland & Stavik, Benedicte [Vis alle 7 forfattere av denne artikkelen] (2022). Single-cell sequencing reveals procoagulant microenvironment in precursor stages of multiple myeloma .
• Dugarte, Maria Eugenia Chollet; Harrison, Sean; Baumgarten, Saphira Felicitas; de la Morena-Barrio, Maria Eugenia; Bravo-Pérez, Carlos & Mowinckel, Marie-Christine [Vis alle 12 forfattere av denne artikkelen] (2022). Human iPSC-derived hepatic organoids – a model for blood coagulation research and therapy. Human Gene Therapy. ISSN 1043-0342. doi: 10.1089/hum.2022.29225.abstracts.
• Cui, Xueyan; Myklebust, June Helen; Munthe, Ludvig A.; Schjesvold, Fredrik Hellem; Tjønnfjord, Geir Erland & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2022). Low expression of coagulation inhibitors in the immune microenvironment in precursor stages of multiple myeloma. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379.
• Cui, Xueyan; Stavik, Benedicte; Sandset, Per Morten & Kanse, Sandip (2022). The role of FSAP in regulating endothelial permeability. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379.
• Andresen, Marianne Seierstad; Mowinckel, Marie-Christine; Stavik, Benedicte; Sandset, Per Morten & Dugarte, Maria Eugenia Chollet (2022). Evaluation of Pharmacological Enhancers of Mutated Factor VII Activity ex vivo. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379.
• Hernes, Toril A. Nagelhus; Sandset, Per Morten; Greve, Gottfried; Brekke, Camilla; Fitjar, Rune Dahl & Hannås, Gøril (2022). Vi har ikke tid til at finansiering av forskning settes på vent. Khrono.no. ISSN 1894-8995.
• Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie [Vis alle 15 forfattere av denne artikkelen] (2022). “Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up”: Reply. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 20(8), s. 1937–1939. doi: 10.1111/jth.15774.
• Dahm, Anders Erik A & Sandset, Per Morten (2021). Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences? Blood Advances. ISSN 2473-9529. 5(11), s. 2516–2517. doi: 10.1182/BLOODADVANCES.2021004651. Fulltekst i vitenarkiv
• andersen, elisabeth; Mowinckel, Marie-Christine; Stavik, Benedicte; Sandset, Per Morten & Dugarte, Maria Eugenia Chollet (2021). High-throughput Screening for Pharmacological Enhancers of Mutated Factor VII Activity. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 5.
• Andresen, Marianne Seierstad; Sletten, Marit; Sandset, Per Morten; Iversen, Nina; Stavik, Benedicte & Tinholt, Mari (2021). Coagulation factor V (F5) is an estrogen-responsive gene in breast cancer cells. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 5.
• Stavik, Benedicte; Andresen, Marianne Seierstad; Holm, Sverre; Skjelland, Mona; Tinholt, Mari & Sandset, Per Morten [Vis alle 8 forfattere av denne artikkelen] (2021). Increased levels of coagulation factor V in atherosclerotic plaques - an immune regulated response? . Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 5.
• andersen, elisabeth; Dugarte, Maria Eugenia Chollet; Sletten, Marit; Stavik, Benedicte; Myklebust, Christiane Fillion & Skarpen, Ellen [Vis alle 11 forfattere av denne artikkelen] (2020). Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding. Blood. ISSN 0006-4971. 136. doi: 10.1182/blood-2020-139219.
• Stavik, Benedicte; Sagen, Ellen Lund; Cui, Xueyan; Holm, Sverre; Dahl, Tuva Børresdatter & Iversen, Nina [Vis alle 8 forfattere av denne artikkelen] (2020). Tissue Factor Pathway Inhibitor induces secretion of pro-inflammatory cytokines in monocyte-derived macrophages. Arteriosclerosis, Thrombosis and Vascular Biology. ISSN 1079-5642. 40.
• Dugarte, Maria Eugenia Chollet; andersen, elisabeth; de la Morena-Barrio, Maria Eugenia; Bravo-Perez, Carlos; Mowinckel, Marie-Christine & Myklebust, Christiane Fillion [Vis alle 12 forfattere av denne artikkelen] (2020). Characterizing Coagulation FVII from iPSC-Hepatocytes-like Cells: Setting the Basis for Cell Therapy Development. Blood. ISSN 0006-4971. 136. doi: 10.1182/blood-2020-139211.
• Kakkos, Stavros K.; Gohel, Manjit; Baekgaard, Niels; Bauersachs, Rupert; Bellmunt-Montoya, Sergi & Black, Stephen A [Vis alle 16 forfattere av denne artikkelen] (2020). Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery. ISSN 1078-5884. 61(1), s. 9–82. doi: 10.1016/j.ejvs.2020.09.023.
• Cui, Xueyan; Tjønnfjord, Geir Erland; Kanse, Sandip; Iversen, Nina; Dahm, Anders Erik A & Myklebust, Christiane Filion [Vis alle 11 forfattere av denne artikkelen] (2019). Tissue factor pathway inhibitor enhances transendothelial migration of chronic lymphocytic leukemia cells trhough CXCL12/CXCR7 chemotaxis. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 3.
• Tinholt, Mari; Stavik, Benedicte; Sletten, Marit; Garred, Øystein; Tekpli, Xavier & Kristensen, Vessela N. [Vis alle 9 forfattere av denne artikkelen] (2019). Coagulation factor V is associated with immune response and tumor lymphocyte recruitment in breast cancer.
• Dugarte, Maria Eugenia Chollet; Andersen, Elisabeth; Skarpen, Ellen; Mowinckel, Marie-Christine; Stavik, Benedicte & Sullivan, Gareth [Vis alle 7 forfattere av denne artikkelen] (2019). FVII: A human pluripotent stem cell derived hepatocyte model with potential therapeutic applications. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 3.
• Andresen, Marianne Seierstad; Stavik, Benedicte; Sletten, Marit; Tinholt, Mari; Sandset, Per Morten & Iversen, Nina [Vis alle 7 forfattere av denne artikkelen] (2019). MicroRNA-494 upregulates TFPI-2 expression in MCF-7 breast cancer cells.
• Sandset, Per Morten & Dahm, Anders Erik Astrup (2019). Is venous thromboembolism a problem in patients with cancer in palliative care? The Lancet Haematology. ISSN 2352-3026. doi: 10.1016/S2352-3026(18)30218-7.
• Schultz, Nina Haagenrud; Holme, Pål Andre; Henriksson, Carola; Mowinckel, Marie-Christine; Sandset, Per Morten & Bratseth, Vibeke [Vis alle 7 forfattere av denne artikkelen] (2019). The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis. Thrombosis Research. ISSN 0049-3848. 177, s. 154–156. doi: 10.1016/j.thromres.2019.03.010.
• Sacco, Simona; Merki-Feld, Gabriele S.; Ægidius, Karen Lehrmann; Bitzer, Johannes; Canonico, Marianne & Kurth, Tobias [Vis alle 15 forfattere av denne artikkelen] (2018). Correction to: Hormonal contraceptives and risk of ischemic stroke in women with migraine: A consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC) (Journal of Headache and Pain (2018) 18 (108) DOI: 10.1186/s10194-017-0815-1). The Journal of Headache and Pain. ISSN 1129-2369. 19(1). doi: 10.1186/s10194-018-0912-9.
• Stavik, Benedicte; Tinholt, Mari; Skjelland, Mona; Espevik, Terje; Sandset, Per Morten & Halvorsen, Bente [Vis alle 7 forfattere av denne artikkelen] (2018). Coagulation factors in human atherosclerotic plaques – a potential link to inflammation?
• Andresen, Marianne Seierstad; Iversen, Nina; Tinholt, Mari; Myklebust, Christiane Filion; Stavik, Benedicte & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2017). Analysis of estrogen mediated expression of TFPI-2 by miRNAs in MCF-7 cells. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 1, s. 408–409.
• Cui, Xueyan; Skretting, Grethe; Tinholt, Mari; Stavik, Benedicte; Dahm, Anders Erik A & Kanse, Sandip [Vis alle 8 forfattere av denne artikkelen] (2017). A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in breast cancer. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 1, s. 395–395.
• Stavik, Benedicte; Espada, Sandra; Holm, Sverre; Bjerkeli, Vigdis; Sandset, Per Morten & Dahl, Tuva Børresdatter [Vis alle 11 forfattere av denne artikkelen] (2017). TFPI in human atherosclerotic plaques. Research and Practice in Thrombosis and Haemostasis (RPTH). ISSN 2475-0379. 1(s1).
• Dahm, Anders Erik A; Jacobsen, Eva-Marie; Jacobsen, Anne Flem; Skuterud Wik, Hilde & Sandset, Per Morten (2017). High complement C3 increases the risk for postnatal venous thrombosis.
• Tikkinen, Kari A.O.; Cartwrigth, R; Gould, Michael K.; Naspro, Richard; Novara, Giacomo & Sandset, Per Morten [Vis alle 8 forfattere av denne artikkelen] (2017). EAU Guidelines on Thromboprophylaxis in Urological Surgery. I James, N'Dow (Red.), European Association of Urology Guidelines 2017. European Association of Urology. ISSN 978-90-79754-91-5. s. 1–18.
• Utne, Kristin Kornelia; Wik, Hilde Skuterud; Jelsness-Jørgensen, Lars-Petter; Sandset, Per Morten; Dahm, Anders Erik A & Tavoly, Mazdak [Vis alle 7 forfattere av denne artikkelen] (2017). Rivaroxaban Reduces the Rate of Post-Thrombotic Syndrome After DVT - a Cross-Sectional Study Comparing Rivaroxaban to Warfarin.
• Stavik, Benedicte; Holm, Sverre; Espada, Sandra; Iversen, Nina; Sporsheim, Bjørnar & Bjerkeli, Vigdis [Vis alle 12 forfattere av denne artikkelen] (2016). Unconventional mechanisms of targeting atherosclerosis.
• Arntzen, Elisabeth & Sandset, Per Morten (2016). E. Arntzen & P.M. Sandset svarer. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 136(12/13), s. 1062–1062. doi: 10.4045/tidsskr.16.0520.
• Stavik, Benedicte; Espada, Sandra; Holm, Sverre; Bjerkeli, Vigdis; Sandset, Per Morten & Dahl, Tuva Børresdatter [Vis alle 11 forfattere av denne artikkelen] (2016). Cholesterol crystals induce TFPI expression in alternatively activated human monocyte-derived macrophages. Vis sammendrag

  Atherosclerotic disease is denoted by low density lipoprotein (LDL) influx and retention in the artery intima, triggering the recruitment of monocytes causing a low grade chronic inflammation. Tissue factor (TF) pathway inhibitor (TFPI) regulates TF induced blood coagulation. Two isoforms exist, TFPIα and TFPIβ. In addition, TFPIα is also found complexed with LDL with unknown function. Moreover, ApoE-/- TFPI-/+ double KO mice display an atherogenic phenotype. We aimed to identify the cells expressing TFPI isoforms in human atherosclerotic plaques and the function of TFPI in these cells.

• Espada Serrano, Sandra; Holm, Sverre; Bjerkeli, Vigdis; Skjelland, Mona; Dahl, Tuva Børresdatter & Iversen, Nina [Vis alle 11 forfattere av denne artikkelen] (2016). ER stress conditions lead to an upregulation of TFPI and is associated with an anti-apoptotic macrophage phenotype. Vis sammendrag

  Endoplasmic reticulum (ER) stress is an important event during the initiation and clinical progression of several cardiovascular diseases, including atherosclerosis. In the present study we determined the role of tissue factor pathway inhibitor (TFPI) under ER stress conditions using human monocyte-derived macrophages (PBMC) and human carotid endarterectomies. TFPI was expressed in carotid plaques from patients with internal carotid stenosis, especially the TFPIα isoform. Moreover, TFPI colocalized with the ER stress marker CHOP in the plaques. Cholesterol crystals (CC) were used in human M1 and M2-polarized macrophages in vitro as an inducer of ER stress. CHOP and TFPI mRNA levels were upregulated after CC treatment, especially in the M2 phenotype. The ER stress inhibitor 4-Phenylbutyric acid (PBA) reversed the CC-mediated upregulation of CHOP and TFPI. Furthermore, M2-polarized macrophages incubated with CC had higher levels of Bcl-2:Bax mRNA ratios and Bcl-2 protein expression, and these effects were reversed by TFPI knockdown and PBA treatment. Our results indicate that TFPI could promote survival of the M2-polarized macrophages under ER stress conditions. These findings may have implications for the pathogenesis of atherosclerosis.

• Skuterud Wik, Hilde; Jacobsen, Anne Flem & Sandset, Per Morten (2015). Long-term outcome after pregnancy-related venous thrombosis. Thrombosis Research. ISSN 0049-3848. 135(1), s. S1–S4. doi: 10.1016/S0049-3848(15)50430-1.
• Utne, Kristin Kornelia; Ghanima, Waleed Khalid; Sandset, Per Morten; Wik, Hilde Skuterud & Jelsness-Jørgensen, Lars-Petter (2015). Long term health-related quality of life after deep vein thrombosis is impaired compared to controls. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13.
• Dahm, Anders Erik A; Tiscia, Gianluca; Holmgren, Asbjørn; Jacobsen, Anne Flem; Skretting, Grethe & Grandone, E. [Vis alle 7 forfattere av denne artikkelen] (2015). Genetic variations in the annexin A5 gene and the risk of pregnancy-related venous thrombosis. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 13(3), s. 409–413. doi: 10.1111/jth.12817.
• Iversen, Per Ole; Negaard, Helene Francisca Stigter; Østenstad, Bjørn; Sandset, Per Morten & Kolset, Svein Olav (2015). Evidence for long term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma. ISSN 1042-8194. 56(8), s. 2479–2481. doi: 10.3109/10428194.2013.803227.
• Stavik, Benedicte; Halvorsen, Bente; Iversen, Nina; Sandset, Per Morten & Skretting, Grethe (2014). Pro-thrombotic environment in atherosclerotic carotid plaques.
• Jacobsen, Anne Flem; Kristiansen, Annette; Bjørge, Line; Henriksen, Tore; Eilertsen, Anette Løken & Sandset, Per Morten (2014). Antikoagulasjon ved venøs trombose i svangerskapet. Tidsskrift for Den norske legeforening. ISSN 0029-2001. s. 926–926. doi: 10.4045/tidsskr.13.1605.
• Jacobsen, Eva-Marie; Dahm, Anders Erik A; Vartdal, Trond & Sandset, Per Morten (2014). Antikoagulasjon ved venøs trombose og indremedisinsk sykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 134(9), s. 924–924.
• Kristiansen, Annette; Brandt, Linn; Berge, Eivind; Dahm, Anders Erik A; Halvorsen, Sigrun & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2014). Nye retningslinjer for antitrombotisk behandling og tromboseprofylakse. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 134(9), s. 921–922. doi: 10.4045/tidsskr.13.1582. Vis sammendrag

  Nye retningslinjer med 250 anbefalinger for antitrombotisk behandling og tromboseprofylakse er nå tilgjengelig på nett. Retningslinjene fra Norsk selskap for trombose og hemostase imøtekommer nye standarder for troverdige retningslinjer og benytter seg av innovative teknologiske løsninger.

• Sandset, Per Morten (2013). Genotype of proband and thrombophilia screening. Blood. ISSN 0006-4971. 122(15), s. 2528–2529. doi: 10.1182/blood-2013-08-519801.
• Narverud, Ingunn; Iversen, Per Ole; Aukrust, Pål; Halvorsen, Bente ; Ueland, Thor & Johansen, Siril Garmannvik [Vis alle 12 forfattere av denne artikkelen] (2013). Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH.
• Tinholt, Mari; Viken, MK; Borresen-Dale, AL; Kristensen, V; Karesen, R & Schlichting, E [Vis alle 12 forfattere av denne artikkelen] (2013). The link between the hemostatic system and cancer: A genotype-phenotype study in breast cancer patients. Thrombosis Research. ISSN 0049-3848. 131, s. S75–S76.
• Ali, Huda Omar; Stavik, Benedicte; Dørum, Elisabeth; Iversen, Nina; Sandset, Per Morten & Skretting, Grethe (2013). Estrogen agonists significantly downregulate TFPI expression in an ER alpha. Thrombosis Research. ISSN 0049-3848. 131, s. S86–S86.
• Bergrem, Astrid; Dahm, Anders Erik A; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2013). Differential risk factors for pregnancy-related deep vein thrombosis and pulmonary embolism - Results from a population-based case-control study. Thrombosis Research. ISSN 0049-3848. 131, s. S75–S75.
• Stavik, Benedicte; Skretting, Grethe; Tinholt, Mari; Sletten, Marit; Sandset, Per Morten & Iversen, Nina (2012). Novel functions of TFPI isoforms in breast cancer cells. Thrombosis Research. ISSN 0049-3848. 129, s. S156–S157.
• Cui, Xue-Yan; Skretting, Grethe; Jing, Y; Myklebust, Christiane Filion; Liu, YF & Sandset, Per Morten [Vis alle 7 forfattere av denne artikkelen] (2012). Hypoxia induces Smad2 phosphorylation signaling and increases stemcell-like properties and multi-drug resistance in K562 leukemic cells. Thrombosis Research. ISSN 0049-3848. 129, s. S191–S192.
• Enden, Tone Rønnaug; Klow, Nils-Einar & Sandset, Per Morten (2012). Catheter-directed thrombolysis for acute deep vein thrombosis Reply. The Lancet. ISSN 0140-6736. 379(9828), s. 1786–1787.
• Skretting, Grethe; Iversen, Nina; Myklebust, Christiane Filion; Dahm, Anders Erik A & Sandset, Per Morten (2012). Apoptosis in CHO-K1 cells overexpressing TFPI involves both intrinsic and extrinsic pathways additional to induced activation of NF-kappa B. Thrombosis Research. ISSN 0049-3848. 129, s. S192–S192.
• Tinholt, Mari; Stavik, Benedicte; Wiiger, Merete Thune; Louch, William Edward; Sletten, Marit & Skretting, Grethe [Vis alle 9 forfattere av denne artikkelen] (2012). TFPI in targeted cancer therapy?
• HELGADOTTIR, LINDA BJØRK; Turowski, Gitta Erika; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Sandset, Per Morten & Roald, Borghild [Vis alle 7 forfattere av denne artikkelen] (2012). Classification of Stillbirths by Cause of Death and Risk Factor Analysis - a Case-control Study. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 91, s. 86–86.
• Wik, Hilde Skuterud; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2012). Long-term impact of venous thrombosis on quality of life, general health and functioning: A cross-sectional, case-control study. Thrombosis Research. ISSN 0049-3848. 130, s. S123–S124. doi: 10.1016/j.thromres.2012.08.061.
• Wik, Hilde Skuterud; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2012). Mortality after pregnancy-related venous thrombosis. Thrombosis Research. ISSN 0049-3848. 130(Supp. 1), s. S124–S124. doi: 10.1016/j.thromres.2012.08.062.
• Ghanima, Waleed Khalid; Lee, Soo Y.; Barsam, Sarah; Miller, Allison; Sandset, Per Morten & Bussel, James B. (2012). Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. British Journal of Haematology. ISSN 0007-1048. 158(6), s. 811–814. doi: 10.1111/j.1365-2141.2012.09227.x.
• Jacobsen, Anne Flem; Henriksen, Tore; Bjørge, Line; Kristiansen, Anette; Kristiansen, Anette & Sandset, Per Morten (2012). Venøs trombose i svangerskapet: Internasjonale retningslinjer blir norske. Gynekologen. ISSN 0805-2158. 3.
• Bergrem, Astrid; Dahm, Anders Erik A; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2012). Differential risk factors for pregnancy related deep vein thrombosis and pulmonary embolism' results from a population-based case-control study. Thrombosis Research. ISSN 0049-3848. 130, s. S122–S123. doi: 10.1016/j.thromres.2012.08.059.
• Skuterud Wik, Hilde; Jacobsen, Anne Flem; Sandvik, Leiv & Sandset, Per Morten (2011). Prevalence and predictors for post-thrombotic syndrome (PTS) three to 16 years after first-time pregnancy related venous thrombosis - a population-based case-control study. Thrombosis Research. ISSN 0049-3848. 127, s. S127–S127.
• Dahm, Anders Erik A; Eilertsen, Anette Løken; Goeman, J.; Olstad, Ole Kristoffer; Øvstebø, Reidun & Kierulf, Peter [Vis alle 9 forfattere av denne artikkelen] (2011). A microarray study on the effect of four hormone therapy regimens on gene transcription in leucocytes from healthy postmenopausal women. Thrombosis Research. ISSN 0049-3848. 127, s. S124–S124.
• HELGADOTTIR, LINDA BJØRK; Skjeldestad, Finn Egil; Jacobsen, Anne Flem; Sandset, Per Morten & Jacobsen, Eva-Marie (2011). Antiphospholipid antibodies and the risk of intrauterine fetal death - Results of a case-control study. Thrombosis Research. ISSN 0049-3848. 127(S3), s. S125–S125.
• Bergrem, Astrid; Dahm, Anders Erik A; Jacobsen, Anne Flem; Mowinckel, Marie-Christine; Sandvik, Leiv & Sandset, Per Morten (2011). Reduced sensitivity to activated protein C in the absence of the factor V Leiden polymorphism is a risk factor for pregnancy related venous thrombosis. Thrombosis Research. ISSN 0049-3848. 127, s. S127–S127.
• Negaard, Helene FS; Sandset, Per Morten; Kolset, Svein Olav; Svennevig, Katja Christiane; Østenstad, Bjørn & Iversen, Per Ole (2011). Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias. Leukemia and Lymphoma. ISSN 1042-8194. 52(6), s. 1157–1159. doi: 10.3109/10428194.2011.563886.
• Ghanima, Waleed; Kleven, Ingrid Wiig; Enden, Tone Rønnaug; Rosales, Antonio; Wik, Hilde Skuterud & Holme, Pål André [Vis alle 7 forfattere av denne artikkelen] (2011). Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 9(6), s. 1261–1263. doi: 10.1111/j.1538-7836.2011.04298.x.
• Stavik, Benedicte; Skretting, Grethe; Sletten, Marit; Sandset, Per Morten & Iversen, Nina (2010). Stable overexpression and knockdown of TFPI in breast cancer cells suggest antitumor properties of TFPI. Thrombosis Research. ISSN 0049-3848. 125, s. S187–S187.
• Skretting, Grethe; Stavik, Benedicte; Solheim, E; Iversen, Nina & Sandset, Per Morten (2010). Sodium butyrate stimulates over-expression of TFPI in CHO-K1 cells. Thrombosis Research. ISSN 0049-3848. 125, s. S172–S172.
• Kleven, I; Rosalis, A; Pederstad, L; Enden, Tone Rønnaug; Sandset, Per Morten & Ghanima, Waleed Khalid (2010). RECURRENT VENOUS THROMBOEMBOLISM AND POST-THROMBOTIC SYNDROME AFTER CATHETER-DIRECTED THROMBOLYSIS IN DEEP VENOUS THROMBOSIS. Haematologica. ISSN 0390-6078. 95, s. 62–62.
• Sandset, Per Morten; Arnesen, Harald; Jacobsen, Anne Flem & Wergeland, Håkon (2010). Prophylaxis against Prosthetic Mitral Valve Thrombosis with Unfractionated Heparin Administered by an Elastometric Infusion Pump. Thrombosis Research. ISSN 0049-3848. 126(3), s. E232–E234. doi: 10.1016/j.thromres.2010.05.005.
• Dahm, Anders Erik A; Bezemer, ID; Sandset, Per Morten & Rosendaal, Frits (2010). Interaction between tissue factor pathway inhibitor and factor V levels on the risk of venous thrombosis. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 8(5), s. 1130–1132. doi: 10.1111/j.1538-7836.2010.03805.x.
• Sandset, Per Morten & Francis, Charles (2010). Thrombosis Research--affiliation with the European Thrombosis Research Organization (ETRO). Thrombosis Research. ISSN 0049-3848. 125, s. 1–1.
• Dahm, Anders Erik A; Bezemer, Irene D; Bergrem, Astrid; Jacobsen, Anne Flem; Jacobsen, Eva-Marie & Skretting, Grethe [Vis alle 8 forfattere av denne artikkelen] (2010). Candidate Gene Polymorphisms and the Risk for Pregnancy Related Venous Thrombosis. Blood. ISSN 0006-4971. 116(21), s. 1708–1709.
• HELGADOTTIR, LINDA BJØRK; Helgadottir, LB; Skjeldestad, FE; Jacobsen, AF; Turowski, G & Roald, B [Vis alle 9 forfattere av denne artikkelen] (2009). Incidence and classification of intrauterine fetal death (IUFD) in the Oslo area 1990-2003. Thrombosis Research. ISSN 0049-3848. 123, s. S137–S137.
• Sandset, Per Morten; Francis, Charles & Key, Nigel (2009). Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research. ISSN 0049-3848. 124(5), s. 515–515.
• Sandset, Per Morten & Francis, Charles (2009). Thrombosis Research: Introduction of e-pages. Thrombosis Research. ISSN 0049-3848. 124(3), s. 25–251.
• Stavik, Benedicte; Skretting, Grethe; Sandset, Per Morten & Iversen, Nina (2009). TFPI sin rolle i kreftfenotyper i brystkreftceller.
• Jacobsen, Anne Flem; Skjeldestad, Finn Egil; Skogstad, Marie Jeanette & Sandset, Per Morten (2009). Epidemiology, risk factors and penetration of venous thrombosis (VT) in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A mutations. Thrombosis Research. ISSN 0049-3848. 123, s. S134–S134.
• Eilertsen, Anette Løken; Lofthus, Cathrine Marie; Høibraaten, Else; Mowinckel, Marie-Christine & Sandset, Per Morten (2009). Differential impact of conventional and low dose oral hormone therapy (HT), tibolone and raloxifene on sex hormone binding globulin (SHBG). Thrombosis Research. ISSN 0049-3848. 123, s. S156–S156.
• Dahm, Anders Erik A; Sandset, Per Morten & Rosendaal, Frits (2008). The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 6, s. 393–395. doi: 10.1111/j.1538-7836.2007.02859.x.
• Stavik, Benedicte; Skretting, Grethe; Sletten, Marit; Frengen, Eirik; Sandset, Per Morten & Iversen, Nina (2008). Stable knockdown of TFPI in cancer cells influences genes involved in angiogenesis.
• Jacobsen, Anne Flem & Sandset, Per Morten (2007). Management of venous thromboembolism (VTE) in pregnancy. Thrombosis Research. ISSN 0049-3848. 119, s. S12–S13.
• Ghanima, Waleed & Sandset, Per Morten (2007). Risk stratification of pulmonary embolism by computed tomography. Journal of Internal Medicine. ISSN 0954-6820. 262(6), s. 702–702. doi: 10.1111/j.1365-2796.2007.1858.x.
• Enden, Tone Rønnaug & Sandset, Per Morten (2010). Towards improvement in deep vein thrombosis; studies on diagnostic MRI, thrombolytic therapy, and quality of life. Unipub forlag.
• Reikvam, Åsmund & Sandset, Per Morten (2010). Warfarinbehandling i praksis - tryggere antikoagulasjon. 2. utgave. Den norske legeforening. ISSN 9788280700834.

Se alle arbeider i Cristin